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ABSTRACT 
Mood disorders are complex psychiatric disorders that are the leading cause of 
disability to work in Finland. They include major depressive disorder (MDD) and 
bipolar disorder (BD). Both are highly heritable, i.e. the variance between 
individuals is, in MDD partly and in BD mostly, explained by genetic factors. Their 
specific genetic background, however, remains widely unknown. Previous linkage 
and association studies have revealed some potential candidate genes and genomic 
areas that seem to predispose to mood disorders, at least in some populations and 
subsamples. Recent genome wide association (GWA) studies have revealed some 
novel susceptibility genes and risk variants as the field has moved into the era of 
genome-wide genotyping of huge samples sizes from collaborative studies. The risk 
variants revealed with this approach, however, cover only a small fraction of the 
total heritability of these diseases. Thus, it is still highly relevant to study samples 
from more genetically and environmentally homogenous populations, since the 
amount of risk variants that are enriched in isolated populations is smaller than in 
more confounded populations. Detailed characterization of the phenotype has also 
become an important factor in psychiatric genetics, since the psychiatric disease 
phenotypes themselves are so broad and heterogeneous. 
The principal goal of this work was to survey functionally relevant candidate genes 
for mood disorders and risk variants revealed from the first GWA studies in a 
Finnish bipolar family sample and in clinical cohorts for mood disorders collected 
from the metropolitan area of Finland. The bipolar family sample comprises 723 
individuals (227 affected for BD) collected utilizing nation-wide registers to identify 
all individuals born between 1940 and 1969 and hospitalized for bipolar disorder 
type I (BDI) between 1969 and 1991. Part of this sample has been characterized in 
more detail enabling the search for genetic susceptibility genes for potential 
endophenotypes of mood disorders. The clinical cohort sample is comprised of 272 
MDD and 178 BD patients, who were characterized for clinical comorbidities and 
followed for long term clinical outcome.  
In the bipolar family sample, the highly studied variant val66met of BDNF was 
found to be associated with BD with the allelic replication observed in previous 
association studies. SLC6A4 allelic variants also showed some association with BD 
 among males, whilst variants of P2RX7 associated with both BD and 
neuropsychiatric test results used to assess executive function. The most statistically 
significant result demonstrated the association of variants of the DAOA gene and the 
general intellectual function of visuospatial ability. The clinical cohort sample 
revealed statistically significant association of two functional variants from P2RX7 
gene with familial form of mood disorder, and both variants affected also the clinical 
outcome of the patients by lengthening the time of illness. Our effort to replicate the 
results from the first GWA studies in the bipolar family sample revealed five 
genomic areas that associated with mood disorder also in Finland. Most of these 
variants also associated with some potential mood-disorder endophenotype, such as 
neurocognitive trait or seasonality in fluctuation of sleep, social activity, or mood. 
In conclusion, the use of detailed characterized samples may provide an advantage 
to the genetic studies, since it increases the possibility of finding the susceptibility 
genes behind more homogenous phenotypes. This work has also revealed some 
potential endophenotypes, or trait features, that might convey the effect of the 
susceptibility genes to the end diagnosis of mood disorder.  
 
Keywords: mood disorder, major depressive disorder, bipolar disorder, candidate 
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 Pia Soronen, Genetics Behind Mood Disorders – Candidate Gene Studies of Bipolar 
and Major Depressive Disorders [Väitöstutkimus mielialahäiriöille altistavista 
geeneistä]. Terveyden ja hyvinvoinnin laitos, Tutkimus 91/2012, 162 sivua. 
Helsinki, Finland 2012.  
ISBN 978-952-245-744-8 (printed); 978-952-245-745-5 (pdf-version) 
 
TIIVISTELMÄ 
Mielialahäiriöt ovat monitekijäisiä psykiatrisia sairauksia, jotka ovat yleisin syy 
työkyvyttömyyteen Suomessa. Mielialahäiriöihin luetaan vakava masennus sekä 
kaksisuuntainen mielialahäiriö. Kummatkin näistä ovat vahvasti perinnöllisiä 
sairauksia, eli geenit vaikuttavat näiden tautien syntyyn. Vakavassa masennuksessa 
geenit vaikuttavat sairauden syntyyn osittain ja kaksisuuntaisen mielialahäiriön 
kohdalla suurelta osin. Vaikka näiden sairauksien geneettistä taustaa on tutkittu 
kauan, vieläkään ei tiedetä mitkä geneettiset tekijät altistavat näille sairauksille. 
Aiemmat geneettiset kytkentäanalyysit ja assosiaatioanalyysit ovat antaneet viitteitä 
tiettyjen geenien ja genomialueiden merkityksestä sairauksien synnyssä. Koko 
genomin sekvensointi ja genotyypitysmenetelmien kehittyminen ovat 
mahdollistaneet koko genomin laajuiset assosiaatioanalyysit isoissa, monen 
tutkimuskeskuksen yhteistyönä keräämissä näyteaineistoissa. Näissä laajoissa 
aineistossa tehdyissä tutkimuksissa on paljastanut täysin uusia alttiusgeeni 
ehdokkaita. Ongelmana on kuitenkin ollut se, että paljastuneet riskimuodot kattavat 
vain pienen osan sairauksien perinnöllisestä taustasta. Tämän vuoksi psykiatrisessa 
genetiikassa on lisäksi tärkeää tutkia myös geneettisesti homogeenisempia 
populaatioita, joihin on kasautunut vähäisempi määrä geneettisiä riskitekijöitä. 
Tärkeäksi tekijäksi on muodostunut myös aineiston tarkka ilmiasun karakterisointi, 
sillä mielialahäiriöt itsessään ovat ilmiasuina erittäin heterogeenisia. 
Tämän tutkimuksen tarkoituksena oli tutkia toiminnallisesti tärkeitä 
mielialahäiriöiden ehdokasgeenejä sekä uusia riskivariantteja jotka on löydetty 
ensimmäisissä koko genomin laajuisissa assosiaatiotutkimuksissa ja selvittää näiden 
vaikutus mielialahäiriöön suomalaisissa aineistoissa. Kaksisuuntaisen 
mielialahäiriön perheaineisto koostuu 723 yksilöstä, joista 227 sairastaa 
kaksisuuntaista mielialahäiriötä ja loput ovat näiden ensimmäisen asteen sukulaisia. 
Osa tästä aineistosta on tarkemmin karakterisoitu neurokognitiivisten 
ominaisuuksien ja vuodenaikais- ja vuorokausimuuttujien osalta. Nämä ovat 
mahdollisia mielialahäiriöiden endofenotyyppejä, eli ominaisuuksia jotka liittyvät 
tutkittavaan psykiatriseen sairauteen ja ovat ilmiasultaan yksinkertaisempia kuin 
tutkittava psykiatrinen sairaus. Kliininen kohorttiaineisto muodostuu 272 vakavaan 
 masennukseen ja 178 kaksisuuntaiseen mielialahäiriöön sairastuneesta. Näiden 
potilaiden kliininen ilmiasu on tarkkaan karakterisoitu komorbiditeettihäiriöiden ja 
sairauden vaikeusasteen osalta.  
Aiemmissa tutkimuksissa paljon tutkittu BDNF geeni ja sen funktionaalinen 
variantti val66met assosioitui perheaineistossa kaksisuuntaiseen mielialahäiriöön. 
Samassa aineistossa myös SLC6A4 geeni assosioitui kaksisuuntaiseen 
mielialahäiriöön miehillä ja P2RX7 geeni sekä kaksisuuntaiseen mielialahäiriöön 
että neurokognitiiviseen testimuuttujaan. Perheaineiston vahvin geneettinen löydös 
oli DAOA geenin assosiaatio visuaalis-tilallista kyvykkyyttä mittaavaan 
neurokognitiiviseen testimuuttujaan. Kohorttiaineistossa löysimme familiaalisen 
mielialahäiriön vahvan assosiaation kahteen P2RX7 geenin aminohappoa 
muuttavaan varianttiin. Kumpikin variantti vaikutti myös kliinisesti lisäten 
riskialleelia kantavien sairastamisaikaa. Neljännessä ja viidennessä osatyössä 
yritimme toistaa ensimmäisten koko genomin laajuisten assosiaatioanalyysien 
tuloksia. Tuloksena oli viiden geenin tai genomialueen assosiaatio mielialahäiriöihin 
myös suomalaisessa aineistossa. Suurin osa näistä assosioitui myös joko johonkin 
neurokognitiiviseen testimuuttujaan tai unen, sosiaalisen aktiivisuuden tai mielialan 
vuodenaikaisvaihteluun, jotka kaikki ovat mahdollisia mielialahäiriöiden 
endofenotyyppejä. 
Yhteenvetona voidaan todeta, että psykiatrisessa genetiikassa on tärkeää käyttää 
tarkkaan karakterisoitua aineistoa, sillä se vähentää tutkittavan ilmiasun 
heterogeenisyyttä ja siten todennäköisyys löytää ilmiasuun vaikuttavia geneettisiä 
riskitekijöitä kasvaa. Tässä työssä tuli myös ilmi joitain mahdollisia 
mielialahäiriöiden endofenotyyppejä ja ominaispiirteitä joiden kautta 
ehdokasgeenien vaikutus sairauteen välittyy. 
 
Avainsanat: Mielialahäiriöt, toistuva vakava masennus, kaksisuuntainen 
mielialahäiriö, ehdokasgeenit, assosiaatioanalyysi, BDNF, P2RX7, DAOA, SLC6A4 
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ABBREVIATIONS 
BD Bipolar Disorder 
BDI Bipolar Disorder type I 
BDII Bipolar Disorder type II 
BDNF Brain derived neurotrophic factor 
bp Base pair 
CDCV Common disease, common variant 
CDH7 Cadherin 7, type 2 
CIDI Composite International Diagnostic Interview 
CNV Copy number variant 
COWA Controlled Oral Word Association Test 
CVLT California Verbal Learning Test 
DAOA D-amino acid oxidase activator 
DFNB31 Deafness, autosomal recessive 31 
DISC1 Disrupted in schizophrenia 1 
DNA Deoxyribonucleic acid 
DSM-IV Diagnostic and Statistical Manual, the fourth edition 
GxE Gene environment interaction 
GWAS Genome wide association study 
HADS Hospital Anxiety and Depression Scale 
hME homogenous Mass Extension 
ICD-10 International Classification of Disease version 10 
JoBS Jorvi Bipolar Study  
kb Kilobase 
LD Linkage Disequilibrium 
MAOA Monoamine oxidase A 
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MDD Major Depressive Disorder 
NOS Not otherwise specified 
PCR Polymerase chain reaction 
PC-VDS Vantaa Primary Care Depression Study 
P2RX7 Purinergic receptor ligand-gated ion-channel 7 
QTDT Quantitative Transmission Disequilibrium test 
r-MDD Recurrent MDD 
SCAN Schedules for Clinical Assessment in Neuropsychiatry 
SCID Structured clinical interview 
SD Standard deviation 
SLC6A4 solute carrier family 6 (neurotransmitter transporter, serotonin), 
 member 4 
SNP Single nucleotide polymorphism 
SORCS2 Sortilin-related VPS10 domain containing receptor 2 
STR Short tandem repeat 
TDT Transmission disequilibrium test 
TPH2 Tryptophan hydroxylase 2 
VDS Vantaa Depression Study 
WAIS-R Wechsler Adult Intelligence Scale – Revised 
WHO World Health Organization 
WMS-R Wechsler Memory Scale-Revised 
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1 INTRODUCTION 
Mood disorders are common in the population and they are the most prevalent 
psychiatric disorders. Mood disorders are the leading cause of morbidity, thus their 
economic impact is huge since they are also the leading cause of disability to work. 
The high suicide rate also makes them fatal disorders, up to 15 % of people suffering 
from mood disorders will eventually commit suicide (Guze and Robins 1970). Mood 
disorders are divided to major depressive disorder (MDD) and bipolar disorder 
(BD). Common to these two disorders are the fluctuation of mood. In MDD, the 
fluctuation is unipolar, comprising only depressive episodes of mood. In BD, the 
fluctuation ranges from extreme elation of mood, mania (BD type I, BDI) or 
hypomania (BD type II, BDII), to depression. The life-time prevalence of MDD in 
Finland is 6.5 % (Pirkola et al 2005) and of BD is 0.24 % (Perala et al 2007).  
The etiology of mood disorders is highly genetic; heritability estimates in MDD vary 
from 40 to 50 % (Levinson 2006) and in BD they range as high as 85-93 % 
(Kieseppä et al 2004; McGuffin et al 2003). The genetic architecture of mood 
disorders is widely studied, but remains vague. The earliest effort to map genetic 
factors behind mood disorders utilized linkage technique where linkage peaks were 
found spread all over the genome for both MDD and BD. The subsequent 
association analyses later found a wealth of potential candidate genes. The 
susceptibility genes are based either on functional relevance of the gene, positional 
mapping of previous linkage findings, or most recently to genome wide association 
(GWA) studies that scan the whole genome more densely than the genome wide 
linkage approach. The most promising candidate genes for mood disorder are brain 
derived neurotrophic factor (BDNF), D-amino acid oxidase activator (DAOA), 
disrupted in schizophrenia 1 (DISC1), tryptophan hydroxylase 2 (TPH2), and solute 
carrier family 6 (neurotransmitter transporter, serotonin), member 4 (SLC6A4) 
(Barnett and Smoller 2009; Levinson 2006; Lohoff 2010), and the genes found in 
GWA studies, such as CACNA1C and ANK3 (Alsabban et al 2011).  
GWA studies were widely called for to better understand the genetics of psychiatric 
disorders, but they have failed to yield the depth of results anticipated (Gershon et al 
2011). Whilst they have indeed revealed new candidates genes for mood disorders, it 
is now evident that the high risk variants cannot be found using the huge 
collaborative samples that are needed for GWA studies, since what is gained with a 
large sample size (power to the statistical analyses), is lost in heterogeneous 
phenotypes. Thus, it remains highly relevant to study more homogenous populations 
with fewer confounding factors and use detailed characterized phenotypes. 
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2 REVIEW OF THE LITERATURE 
2.1 Overview of Mood Disorders 
Mood disorders, also known as affective disorders and manic-depressive illnesses, 
are defined by abnormal fluctuation of mood. They include BD and MDD, which is 
also known as unipolar disorder, and BD. MDD is characterized by major depressive 
episodes that affect patients’ ability to function. BD patients have had at least one 
episode of abnormally elevated mood, which can be either hypomania (BDII) that 
does not affect social or occupational functioning, or mania (BDI) that either affects 
social and occupational functioning, requires hospitalization, or contains psychotic 
features (Goodwin and Jamison 2007).  
MDD and BD can be seen either as two different disease entities (the categorical 
view) or as the ends of the same manic-depressive disease spectrum (the spectrum 
view) (Goodwin and Jamison 2007). Both categorical and spectrum views have 
supporting findings in the literature (Benazzi 2007). The categorical view is 
supported by findings such as: gender distribution of MDD and BD differs (female 
dominance in MDD, equal prevalence in BD) (Angst and Marneros 2001); brain 
structure abnormalities of MDD are different to those of BD (Kempton et al); and 
the family distribution of BD and MDD cases differs between mania and depressive 
patients (Winokur et al 1995). The spectrum view is supported by the fact that in 
both, the depression is present either with or without hypomania or mania. In 
addition, the existence of hypomania and the mood continuum from normal to 
manic, the existence of fluctuation of mood in both disorders (recurrent-MDD, r-
MDD and BD), high rate of MDD diagnoses shifting to BD, and similarities in 
cognitive performance (Benazzi 2007) support the spectrum view of mood 
disorders. 
2.1.1 Historical aspects 
Primitive societies thought that mental disorders were caused by magical forces, but 
in ancient Greece they were already seen as symptoms of underlying biological 
disturbances (Goodwin and Jamison 2007). The first classification categories of 
mental disorders were defined by Hippocrates (460 – 337 BCE), and included 
melancholia, mania and paranoia (Angst and Marneros 2001). The first noted 
suggestion that melancholia and mania are associated is dated back to the year 120 
(Goodwin and Jamison 2007) when Arateus wrote that mania is a worsening of 
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melancholia (Angst and Marneros 2001). In 1854, French psychiatry Jean-Pierre 
Falret defined bipolar disorder as one disease entity for the first time, which he 
referred to as “circular disorder” (la folie circulaire), although most clinicians treated 
mania and melancholia as separate disease entities at that time (Goodwin and 
Jamison 2007). Melancholia and mania were considered the terms for mental 
illnesses in a broader sense than they are nowadays: these terms also captured some 
types of schizophrenia spectrum disorders (Angst and Marneros 2001). It was not 
until the late 19th century, when Emil Kraepelin segregated schizophrenia (dementia 
praecox at that time) from manic-depressive illness, and he also stated that all 
recurrent affective diseases belong to one illness spectrum, manic-depressive illness. 
This view dominated for decades, until the year 1966, when the opposite views 
gained ground in the psychiatric field when Jules Angst and Carlo Perris 
independently published family history data showing that patients suffering mania 
have a higher rate of mania in their families compared to patients suffering only 
recurrent depression and that these two disorders have distinct clinical features and 
course (Angst and Marneros 2001; Perris 1966). Nowadays there are three different 
diagnostic groups; MDD, BDI, and BDII, where MDD faces the strongest resistance 
because it is too wide a category, containing a plentitude of different clinical 
subtypes (Goodwin and Jamison 2007; Winokur 1979)  
2.1.2 Diagnostic perspectives 
The whole history of psychiatric diagnoses has been full of changes and overlaps in 
classification systems (Goodwin and Jamison 2007). Nowadays, there are two 
distinct diagnostic systems: the International Classification of Disease version 10 
(ICD-10) (WHO 1992) and the Diagnostic and Statistical Manual, the fourth edition 
(DSM-IV) (American Psychiatric Association 1994). The ICD-10 is in use in 
clinical work in Finland, and in most of the world. The DSM-IV is in use in research 
and also in clinical work in United States. There are some differences between these 
two classification systems. For example, there are only two core symptoms in DSM-
IV major depressive diagnosis (depressed mood and loss of interest or pleasure) and 
only one is needed for diagnosis. This is contrary to the ICD-10, where also fatigue 
and loss of energy is one of the core symptoms, and two core symptoms are needed 
for diagnosis. In addition, ICD-10 major depressive diagnosis requires overall only 
four symptoms, which is one symptom less compared to DSM-IV. In DSM-IV, BD 
is split into two main categories: BDI and BDII. In this study, DSM-IV diagnostic 
criteria are used for patient classification unless otherwise specified. The DSM-IV 
diagnostic criteria for major depressive episode and mania are summarized in Table 
1 and Table 2, respectively. 
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Table 1. Diagnostic criteria for Major depressive episode according to DSM-IV 
(American Psychiatric Association 1994). 
 
A Five (or more) of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning; at least one of the symptoms 
is either (1) depressed mood or (2) loss of interest or pleasure. 
1. Depressed mood most of the day, nearly every day, as indicated by either subjective 
report or observation made by others 
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, 
nearly every day 
3. Significant weight loss when not dieting or weight gain (e.g., a change of more than 
5% of body weight in a month), or decrease or increase in appetite nearly every day 
4. Insomnia or hypersomnia nearly every day 
5. Psychomotor agitation or retardation nearly every day (observable by others, not 
merely subjective feelings of restlessness or being slowed down) 
6. Fatigue or loss of energy nearly every day 
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being sick) 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either 
by subjective account or as observed by others 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without 
a specific plan, or a suicide attempt or a specific plan for committing suicide 
B. The symptoms do not meet criteria for a Mixed Episode. 
C. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning. 
D. The symptoms are not due to the direct physiological effects of a substance (e.g., a 
drug of abuse, a medication) or a general medical condition (e.g., hypothyroidism). 
E.  The symptoms are not better accounted for by bereavement, i.e., after the loss of a 
loved one, the symptoms persist for longer than 2 months or are characterized by 
marked functional impairment, morbid preoccupation with worthlessness, suicidal 
ideation, psychotic symptoms, or psychomotor retardation. 
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Table 2. Diagnostic criteria for mania episode according to DSM-IV (American 
Psychiatric Association 1994). 
 
A. Distinct period of abnormally and persistently elevated, expansive or irritable mood, 
lasting at least 1 week (or any duration if hospitalization is necessary) 
B. During the period of mood disturbance, three (or more) of the following symptoms 
have persisted (four if the mood is only irritable) and have been present to a significant 
degree: 
1. Inflated self-esteem or grandiosity 
2. Decreased need for sleep (e.g., feels rested after only 3 hours of sleep) 
3. More talkative than usual or pressure to keep talking 
4. Flight of ideas or subjective experience that thoughts are racing 
5. Distractibility (i.e., attention too easily drawn to unimportant or irrelevant external 
stimuli) 
6. Increase in goal-directed activity (at work, at school, or sexually) or psychomotor 
agitation 
7. Excessive involvement in pleasurable activities that have a high potential for painful 
consequences (e.g., engaging in unrestrained buying sprees, sexual indiscretions, or 
foolish business investments) 
C. The symptoms do not meet criteria for a Mixed Episode 
D. The mood disturbance is sufficiently severe to cause marked impairment in 
occupational functioning or in usual social activities or relationships with others, or to 
necessitate hospitalization to prevent harm to self or others, or there are psychotic 
features 
E. The symptoms are not due to the direct physiological effects of a substance (e.g., a 
drug of abuse, a medication or other treatment) or a general medical condition (e.g., 
hyperthyroidism) 
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MDD is split into two main diagnostic categories, either MDD with single major 
depressive episode, or recurrent MDD (r-MDD) that requires at least two major 
depressive episodes in a lifetime. Thus r-MDD contains a wide spectrum of MDD 
disease types from two mild major depressive episodes to highly recurrent and 
severe major depressive episodes with psychotic features. BD is similarly divided 
into two categories: BDI, where the patient must have had at least one episode of 
mania; and BDII, where patients must have had at least one episode of hypomania in 
a lifetime.  
Some studies argue that 20 to 24% of MDD patients are misdiagnosed BD patients 
(Hu et al 2012; Muzina et al 2007; Smith et al 2011a; Tafalla et al 2009). The proper 
diagnosis is crucially important, since the medication of BD with only 
antidepressant monotherapy could lead to impairment in the course of illness by 
leading to rapid cycling or turning the mood to mania or hypomania (Altshuler et al 
1995; Wehr and Goodwin 1987), lowering the patient’s quality of life (Awad et al 
2007), and increasing the risk of attempting suicide (Shi et al 2004). The diagnosis 
of BD in depressive patients is based on retrospective identification of hypomania or 
mania symptoms, so there might easily be misdiagnoses because of a lack of 
anamnesis. Because of this difficulty in diagnostics, there are studies that have tried 
to find clinical differences in depressive symptoms of BD and MDD: in BD there is 
a greater risk for suicide (Moreno and Andrade 2010; Schaffer et al 2010), more 
lifetime depressive episodes, earlier age of onset, more substance abuse, more 
insomnia, decreased concentration, more psychomotor agitation and 
guilt/worthlessness (Schaffer et al 2010), and higher prevalence of atypical features 
of depression such as hypersomnia, increase in appetite and/or weight gain (Moreno 
and Andrade 2010). 
There is at least some genetic overlap between MDD and BD, an approximate 
estimate of the shared genetic variance, i.e. heritability, is about 30 % (McGuffin et 
al 2003). Family studies show that the shared genetic risk is evident, although there 
are some discrepancies, for example, probands of BD have an elevated risk for both 
BD and MDD, whereas probands of MDD have an elevated risk for only MDD 
(Smoller and Finn 2003). 
There is evidence that overlap also exists with other psychiatric disorders, such as 
schizophrenia and mood disorders, when examining clinical features, including 
course of illness, brain imaging, molecular neurobiology and genetics (Kempf et al 
2005). The symptom of psychosis is the most evident evidence of the overlap of 
these disorders; in large clinical samples the amount of psychotic cases among MDD 
was estimated to be 18 %, and among BD it was as high as 52 % (Souery et al 
2011). In study by Maier et al., first degree relatives of schizophrenia, BD, and 
MDD probands were diagnosed to provide evidence for a common genetic 
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background of schizophrenia and MDD, but not schizophrenia and BD (Maier et al 
1993). In contrast, an extensive register study from Sweden showed that relatives of 
BD probands have an increased risk for schizophrenia, thus implying that there is 
likely a partly common genetic background for these two disorders (Lichtenstein et 
al 2009). A common genetic background is further supported by the novel GWA 
studies that have found a huge amount of common association findings for BD and 
schizophrenia (Huang et al 2010; Moskvina et al 2009; Purcell et al 2009; Williams 
et al 2011a; Williams et al 2011b).  
2.1.3 Epidemiology 
There is a range of prevalence estimations for mood disorders in different 
populations. In the United States, the life-time prevalence of MDD is 16.2 %, BD-I 
1.0 %, and BD-II 1.1 % (Merikangas et al 2007). In general, the estimates of 
prevalence of MDD varied between 10 and 15 percent (Lohoff 2010) and of BD 
between 0.8 and 2.6 percent (Kato 2007). In Finland, the prevalence estimates are 
smaller: 6.5 % for MDD (Pirkola et al 2005) and 0.24 % for BD (Perala et al 2007). 
The lower prevalence of BD in Finland compared to other populations is 
hypothesized to result from higher age of onset seen in study of Räsänen et al. 
(Rasanen et al 1998), but other explanations must exist. There is a clear gender 
difference in prevalence of MDD with females having twice as high prevalence 
compared to males (Craddock and Forty 2006; Kessler et al 1994), but this gender 
difference is not seen in BD cases. The age of onset of MDD is nearly decade later 
than that of BD; in a large clinical study from Sardinia, the median age of onset was 
32 (Tondo et al 2010), and in a smaller Norwegian sample it was 28 years 
(Oedegaard et al 2009). The mean age of onset in BD, in contrast, has been 
estimated to be 21 to 23 years (Craddock and Forty 2006; Tondo et al 2010). 
2.1.4 Aetiology 
M a j o r  d e p r e s s i v e  d i s o r d e r 
The factors that lead to MDD are highly complex, consisting of genetic and 
environmental factors that are specific to individuals (Sullivan et al 2000). The 
genetic influence is substantial, the heritability estimates vary from 33 to 50 % 
(Craddock and Forty 2006; Levinson 2006; Sullivan et al 2000). The risk for a first 
degree relative of an MDD proband to develop MDD is two to three fold more than 
individuals from the general population (Levinson 2006). Heritability seems to be 
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partly distinct between men and women (Kendler et al 2001), and it is higher in 
early onset (before 30 years) versus late onset (after 30 years) forms of the disease 
(Lyons et al 1998).  
The environmental factors leading to depression include childhood sexual abuse 
(Kendler et al 2004), stressful life events (Kendler et al 2004), maternal anxiety in 
late pregnancy (O'Connor et al 2003), and loss of parent (Tennant 1988). 
Environmental factors seem to be specific to individuals, it has been shown that the 
common environmental factors affecting heritability is zero (Sullivan et al 2000). 
It has been postulated that there are at least four different subtypes of depressive 
disorders depending of the familial pattern of MDD or co morbidity disorders: 1) 
sporadic depressive disorder with no familial background; 2) pure depressive 
disorder with familial loading of MDD; 3) depressive-spectrum disorder with 
familial loading of MDD, alcoholism or sociopath; 4) bipolar variant (mood disorder 
spectrum) with familial loading of BD (Winokur et al 1971). Some kind of grouping 
system would be highly beneficial not only for genetic studies, but also for clinical 
practice, e.g. for choosing a suitable treatment method, because there is evidence 
that the groups differ biologically and thus, most probably also, genetically. For 
example, it has been shown in the late 1970s that familial background has an effect 
on the activity of the hypothalamic-pituitary-adrenal axis such that the regulation of 
cortisol secretion was disturbed mostly in the pure depressive-disorder group 
(Schlesser et al 1979). There are studies that have tried to find the clinical markers 
that predict higher familial loading and those include cases with early age of onset 
(Kendler et al 2007; Levinson et al 2003; Weissman et al 1984), cases that meet 
most of the symptomatic DSM criteria (Kendler et al 2007), and those who suffer 
recurrences (Kendler et al 2007; Levinson et al 2003). 
 
B i p o l a r  D i s o r d e r 
The positive family history of affective disorder is the most reliable risk factor for 
BD. The heritability estimates for BD ranged from 85 (Kieseppä et al 2004) to 93 % 
(McGuffin et al 2003). The risk for BD of a first degree relative of a BD proband is 
9 %, compared to a 1 % risk for the general population (Barnett and Smoller 2009). 
Relatives of a BD proband are also more vulnerable to other psychiatric disorders, 
such as MDD and schizophrenia (Craddock and Sklar 2009) 
Bipolar disorder, as well as other common psychiatric disorders, have long been 
considered to be a consequence of common variants (common disease common 
variant, CD/CV theory), but in light of the current knowledge, it is only partly true. 
It has recently been estimated, using GWAS data, that around 40 % of heritability of 
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BD is explained by common variants, i.e. is captured by GWA data (Lee et al 
2011b). There has been a widespread debate where the missing heritability lies.  
Other suggestive risk factors for BD are obstetric complications, winter/spring birth, 
stressful life events, traumatic brain injuries, multiple sclerosis, childbirth (Tsuchiya 
et al 2003), and urban birth place (Mortensen et al 2003). The parent or sibling lost 
in childhood has shown to be an important risk factor, especially maternal loss 
before the age of five (Mortensen et al 2003). 
2.1.5 Endophenotypes 
The term “endophenotype” first emerged in the literature in the year 1966, when an 
insect geneticist used the word for describing differences in chromosome numbers 
between distinct insect populations (John and Lewis 1966). Thus the term 
endophenotype referred to an internal phenotype that was not visible to the naked 
eye, contrary to the “exophenotype” (external phenotype). The term was later 
adapted to psychiatric genetics by Gottesman and Shields. They hoped to find 
schizophrenia endophenotypes that would segregate in a monogenic way among 
schizophrenics, thus facilitating the search of genetic factors for schizophrenia 
(Gottesman and Shields 1973). Nowadays, endophenotype is defined as an 
intermediate component between complex disease and distal susceptibility genes 
(Gottesman and Gould 2003). The concept assumes that the genetic background of 
endophenotype is simpler than the genetic background of the disease, not as simple 
as it was thought in the 1960s and 1970s, but involving fewer genes than the disease 
phenotype.  
The criteria for identification of endophenotypes according to Gottesman & Gould 
are: 
1. In a population, the endophenotype is associated with the illness. 
2. The endophenotype is heritable. 
3. The endophenotype is state-independent, i.e. it manifest in spite of individuals 
episode. 
4. The endophenotype and illness co-segregate in families. 
5. The endophenotype is more frequent in the unaffected family members of 
probands than in the normal population. 
The concept of endophenotype could help researchers to simplify the genetic basis 
of highly complex phenotypes, such as MDD and BD. These disease entities are 
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based on clusters of symptoms and clinical characteristics that are highly 
heterogeneous. The endophenotypes were initially assumed to be more 
homogeneous with simpler genetic architecture.  
Potential endophenotypes for mood disorders include various neuropsychological, 
biochemical, neuroanatomical, or cognitive traits, such as abnormal regulation of 
circadian rhythms, response to sleep deprivation, response to cholinergics, deficits in 
attention, and increase in white matter hyperintensities (Hasler et al 2006; Lenox et 
al 2002).  
Various aspects of cognition and other brain functions are good endophenotype 
candidates for BD (Glahn et al 2004; Hasler et al 2006; Robinson and Ferrier 2006). 
The heritability of general intelligence has been most extensively studied and it has 
been shown to have a strong genetic background (Devlin et al 1997; McClearn et al 
1997). There are also data showing that specific cognitive functions, such as 
executive functioning, verbal ability, attention, spatial and verbal working memory, 
and processing speed are remarkably heritable (Ando et al 2001; Antila et al 2007b; 
Fan et al 2001; Finkel et al 1995; Luciano et al 2001). According to many studies, 
the most promising cognitive function endophenotype for BD seems to be executive 
functioning, verbal memory, processing speed (Antila et al 2007a; Frantom et al 
2008; Glahn et al 2004; Hasler et al 2006; Robinson and Ferrier 2006). Good 
endophenotypes for psychotic disorders are shown to include executive function and 
semantic fluency (Hu et al 2011). Novel GWAS findings have revealed common 
genome-wide significant association findings for BD and schizophrenia (O'Donovan 
et al 2008), and this same variant has also shown to disturb the connection of brain 
areas, thus providing a potentially mechanistic endophenotype for psychotic 
disorders (Esslinger et al 2009). A recent study searched for potential 
endophenotypes for MDD and it revealed Beck Depression Inventory, bilateral 
ventral diencephalon volume, and expression levels of the RNF123 transcript (Glahn 
et al 2012). In addition, new magnetic resonance imaging (MRI) techniques are 
proposed to be valuable in searching for genuine endophenotypes for MDD (Hasler 
and Northoff 2011). 
Endophenotypes could have a broader use in psychiatry than just as a tool for 
genetic studies. They could be exploited in diagnostic procedures as well as in the 
development of new and possibly individually tailored cure, by enabling clinician to 
subgroup patients into more homogenous groups that might also differ in sensitivity 
to drugs. 
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2.2 Genetics of complex diseases 
The field of genetics has evolved enormously within the last decade after the 
complete sequencing of the whole human genome (Lander et al 2001; Venter et al 
2001). Before the availability of the whole human genome sequence, genetic 
research was concentrated on mapping of risk areas by linkage and positional 
cloning of candidate regions. A number of so-called classical monogenic traits were 
successfully characterized by linkage studies taking advantage of the Mendelian 
inheritance model and family structures. However, the more common multifactorial 
diseases, such as diabetes and psychiatric illnesses, have not been proven to be as 
successful in genetic vulnerability research (Zondervan and Cardon 2004). New 
strategies of whole genome associations and sequencing are sought, but current 
approaches do not yet meet expectations in psychiatric genetics.  
2.2.1 Heritability 
Heritability is the proportion of phenotypic variance that is due to inherited genetic 
factors. It varies from zero to one; where zero means that the phenotype is not 
affected by genes but is rather a consequence of environmental factors alone, and 
one means that all the variance seen in the phenotype is a result of genes. Thus, 
heritability is extracted from the total phenotypic variance that is not due to 
environmental factors. This extraction can be made either by using adoption or twin 
data. The most optimal are adoption studies, where the phenotypic variance of 
monozygotic twins adopted to distinct families (= environment) is completely due to 
the environmental variance. Hence heritability estimates are more accurate in 
adoption studies, since there are no confounding effects of shared environment. 
Adoption studies are not that easily available, thus most heritability estimates in 
complex genetics are established using twin data. Twin studies are based on the 
assumption that monozygotic and dizygotic twins share the environmental variance, 
but only monozygotic twins share also all the genetic variance, whereas dizygotic 
twins share on average half of it. Therefore, if monozygotic twins’ phenotype is 
more similar than dizygotic twins, there is genetic variance, i.e. heritability, 
affecting the total variance of the phenotype.     
Heritability can mean two different concepts. In a broad sense, it refers to all the 
genetic variance of heritability, i.e. additive, dominance, and epistasis. Dominance 
variance means the effect of interaction of alleles in a given locus to the phenotype, 
whilst the epistasis means the effect of interaction of alleles at distinct loci to the 
phenotype. Additive genetic variance indicates the sum of effects of all loci affecting 
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the phenotype that does not take into account the interactions, and it also refers to 
the narrow sense of heritability.  
2.2.2 Human genome  
The following section outlines the historical milestones of defining the human 
genome in addition to the associated major advances in genetic research. Darwin 
was the first to introduce the concept of natural selection and inheritance to a wider 
audience (Darwin 1859). A decade later, Mendel introduced the famous pea crossing 
studies that demonstrated that there are small hereditary units that can be predicted 
by statistical rules (Mendel 1866). Then in 1953, the structure of the hereditary unit 
was exposed when Watson and Crick revealed the structure of deoxyribonucleic 
acid (DNA) (Watson and Crick 1953) and in 1956 it was established that the human 
genome constitute of 46 diploid chromosomes (Tjio and Levan 1956). 
Chromosomes are composed of large DNA molecules and a wide variety of proteins 
that are attached to the DNA sequence and which function, for example, to tightly 
package the DNA molecule.  
Currently, the human genome is known to be constituted of 3.2 x 109 pairs of 
nucleotides that are nearly identical between individuals. The estimate of the genetic 
variance between individuals is 0.1 % (The International HapMap Consortium 2005) 
and the repertoire of genetic variation is wide. It ranges from single nucleotide 
polymorphism (SNP) to chromosome number variation and these variations induce 
the difference between individuals together with recombination and epigenetic 
differences such as distinct methylation patterns. 
The estimates of the amount of protein coding genes in the human genome have 
varied considerably over the years they have been studied. The first estimate after 
whole genome sequencing was 30 - 40,000 genes (Lander et al 2001), but in the 
light of current knowledge, the number of protein coding genes is only around 
21,000 (Clamp et al 2007). The concept of “gene” has evolved enormously in 
tandem with the sequencing of the human genome, and other species’ genomes, has 
been completed. First, alternative splicing seems to be centrally important in 
defining the diversity of proteins produces, more so than gene number. Alternative 
spicing takes place in more than 90 % of genes. Gene duplication is also an 
important method for defining new proteins, the appearance of completely novel 
proteins is an extremely rare event. Second, it has been surprising that the vast 
majority of functional sequence does not encode proteins at all. The protein coding 
genes encompass only 1.5 % of the genome, but according to the comparison of the 
human and mouse sequences, the functionally relevant sequence encompass 6 % of 
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the genome (Waterston et al 2002), thus the protein-centric thinking in search of 
functional variants behind complex diseases does not cover the whole functionally 
important variance between individuals. These non-protein coding sequences 
contain significant roles, including regulatory areas important in embryonic 
development (Pennacchio et al 2006), but the function of vast majority of them is 
still unknown. Third, transposons are revealed to be important drivers of evolution. 
Finally, non-protein coding transcripts are fundamental part of the genome, 
containing both small non-coding RNAs calling microRNAs that regulate the 
translational activity of mRNAs and also large RNAs with still mainly unknown 
functions (Lander 2011).  
 
V a r i a t i o n  i n  t h e  h u m a n  g e n o m e 
A SNP is a one base substitution in nucleotide sequence and there are both rare and 
common variants, implicating both different genealogical age of the variant and 
variants influence to the fitness. Most SNPs are neutral variants whose frequency is 
a consequence of genetic drift, however a small number are functional variants that 
have beneficial or harmful effect on the fitness of an individual. The vast majority of 
SNPs with over 5 % frequency have been discovered and it has been estimated that 
95 % of SNPs can be found in public databases (Lander 2011). SNPs are widely 
used variants in association studies since they are abundant in the genome, they have 
low mutation rate, ease of genotyping in high-throughput manner, and they are 
mostly di-allelic which also renders them good variants to use in haplotype maps 
(more in next chapter). The amount of common SNPs (frequency over 5 %) in the 
genome is estimated to be 9–10 million (Frazer et al 2007), so there is approximately 
one SNP per 300 bp.   
Microsatellites, also known as short tandem repeats (STR) are another variant type 
which are traditionally used in genetic analyses. STRs are multiallelic variants that 
consist of two to 13-base repeats. Di-, tri- or tetra-nucleotide repeats variants are 
used in linkage studies (Litt and Luty 1989; Weber and May 1989), where the 
multiallelic marker inheritance, together with the disease or trait studied, is 
examined in large pedigrees or sibling pairs.   
There are also other types of repeat variants in the genome. STR markers belong to 
the simple sequence repeats that also comprise satellite markers where the repeat 
sequence is over 500 bp long and minisatellites where the repeat sequence is 14 to 
500 bp long. Transposons are also repeat sequences that comprise almost half of the 
human genome sequence. They are capable to shift positions within and between 
genomes and they are therefore important players in evolution.  
 THL – 91/2012  27  Genetics Behind  
Mood Disorders 
Copy number variants (CNV) are also referred to as repeat variants that are 
composed of relatively long sequence (over 1 kb) that can contain gene(/s) and the 
number of copy variation ranges from zero to six. There are both common CNVs 
that are estimated to cover 3 Mb in a typical individual, as well as rare CNVs that 
are thought to derive from recent mutations (Lander 2011). CNV are found to be 
important factors inducing genetic variance between individuals and their role in 
psychiatric disorders are widely studied (Lee et al 2012).   
The largest variances in the human genome are chromosomal abnormalities that can 
be seen by eye at the microscopic level. Whole chromosome deletions and 
duplications cause syndrome phenotypes such as Down syndrome (21 trisomy) and 
Klinefelter’s syndrome (XXY). Inversions are DNA segments that are rotated in the 
chromosome and they can be also neutral, i.e. not causing any symptoms to the 
carrier. Translocations are chromosomal regions that have switched positions from 
one chromosome to other and those are abundant in cancer cells.  
2.2.3 Linkage disequilibrium 
Linkage disequilibrium (LD) is a central concept in complex trait genetics. The term 
LD means that two alleles at different loci do not segregate randomly. These two 
loci need not be in the same chromosome, although in complex genetics the term is 
used mainly to examine the genetic distance of two loci within the same 
chromosome. LD is used when constructing haplotype blocks, which were 
introduced after the sequencing of the human genome (Daly et al 2001). The 
haplotype blocks are separated by recombination hot spots, which means that the 
recombination preferentially happens in a particular area of the sequence and these 
areas differ between species (Paigen and Petkov 2010). The haplotype blocks enable 
researchers to do association studies with only a fraction of SNPs and still capture 
most of the variation in the human genome. This is possible since it has been shown 
that SNPs in one haploblock comprise haplotypes (that is allele combinations of 
adjacent loci) that have only a limited amount of diversity. Most of the diversity 
between individuals can be captured by genotyping only 6 to 8 SNPs within one 
haplotype block (Gabriel et al 2002); these SNPs are called haplotype tagging SNPs. 
The tightly linked loci construct haplotype blocks that in humans can span from  a 
few kilobases (kb) to several hundred kb (Wall and Pritchard 2003). The haplotype 
map of the entire human genome was established in 2005 (The International 
HapMap Consortium 2005). The haplotype blocks differ between human 
populations partly due to the allele frequency differences. With this haplotype 
tagging SNP method, researchers can capture most of the common variation in the 
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human genome, but the rare variants and possibly also the associations of functional 
variants can be missed (Terwilliger and Hiekkalinna 2006).  
2.2.4 Genetic mapping of complex diseases 
Large scale genetic mapping became possible after the use of neutral DNA sequence 
polymorphisms was proposed in the construction of a genetic map that could be 
systemically used to hunt the chromosomal regions that transmit together with the 
disease in a pedigree (Botstein et al 1980). Genetic mapping is based on the variants 
in the genome that are neutral, i.e. they do not affect the fitness or the phenotype of 
the individual but they are linked to the causative variant. So the genotype markers 
define the genomic area that contains a gene variant or other sequence variant that 
predisposes to a phenotype of interest. The ultimate goal is to find the causative 
variant that increases the risk of the disease, but in complex disease genetics, these 
methods have not been as effective as in the case of Mendelian diseases where only 
one gene is responsible for the phenotype. The genetic mapping of complex diseases 
use STR and SNP markers, and the methods employed are either linkage or 
association based mapping. 
 
L i n k a g e  s t u d i e s 
The linkage method uses highly variable STR markers (Litt and Luty 1989; Weber 
and May 1989) to identify genomic areas that are inherited together with the disease 
(or other phenotype) in a pedigree or in sibling pairs. The method is based on the 
fact that the chromosomal areas that contain the susceptibility genes are inherited 
with the disease more often than is expected by chance (Morton 1955). This method 
would be suitable for complex diseases in which the genetic risk is caused by a 
relatively small number of genes with relatively large effects. It has been a highly 
effective method when searching the genetic vulnerability areas for rare, monogenic 
diseases (Botstein and Risch 2003) such as the Finnish heritage diseases like 
aspartylglucosaminuria (AGU), but in complex diseases it has not been as 
successful. This has lead to the hypothesis that most complex diseases, like common 
psychiatric diseases are a consequence of common variants that have relatively 
small effect on the risk; this is called the “common disease common variant” 
hypothesis (CDCV) (Reich and Lander 2001). 
The linkage method uses either large pedigrees or affected sibling pairs. The linkage 
analyses are based on the calculations of genetic distance between markers and the 
predisposing variant. The distance is characterized by recombination fraction (θ, 
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theta), that is, the amount of meiotic events of recombination that these two loci are 
separated by. The recombination fraction (centimorgan) is proportionate to physical 
distance: one centimorgan corresponds to about one million base pairs on average, 
although the recombination rate varies greatly between chromosomes (Yu et al 
2001).  
 
A s s o c i a t i o n  a n a l y s e s 
In association analysis, the allele frequencies of cases and controls are examined and 
it is proposed that if the allele is more frequent in cases than controls, it associates 
with the phenotype and it, or some other marker allele that is in LD with the 
associating allele, increases the risk of phenotype. It has been proposed that 
association analyses are more suitable for detecting susceptibility genes for complex 
disorders where single genes confer only modest increased risk for the disease and 
where the susceptibility variants are thought to be relatively common (Risch and 
Merikangas 1996). In addition to single locus analyses, haplotypes can also be used 
in association studies. This enables the examination of larger genomic areas, but it 
requires that haplotype estimations must be made (Ott et al 2011).  
Associating analyses can also be performed with family data. This carries an 
advantage over case-control data as it avoids control sample bias that can be 
problematic. In order to avoide the bias in case-control samples, the control sample 
must be selected carefully, since they must be comparable to cases so that the 
genetic differences between case and control populations would not bias the 
association results. There are several programs that analyse the association of family 
data. Those use either haplotype-relative risk (HRR) or transmission disequilibrium 
test (TDT) methods to dissect the association signal from family data. Both are 
based on calculations in which parental alleles are classified as either transmitted or 
not-transmitted to the affected offspring (Ott 1989). The TDT is a modification of 
HRR, and it tests linkage in the presence of LD using data from parents and affected 
offspring. There are several modifications of the TDT method, for example the 
ability to also use quantitative phenotypes in the analyses (Horvath et al 2001).  
 
Candidate gene studies 
Candidate gene studies are usually based on previous linkage findings and 
subsequent positional cloning of the linkage area and/or a priori hypotheses of the 
importance of the gene function concerning the phenotype of interest. In candidate 
gene studies, the problem is how to deal with a multiple testing problem and the low 
effect sizes of associating variants. To obtain statistically significant results, the 
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sample size request is usually high, since the effects of the associating variants to the 
complex diseases are from low to modest (Cardon and Bell 2001; Owen et al 1997). 
A statistical P-value of 0.05 is not strict enough when doing multiple tests in the 
same study, but the other extreme of Bonferroni corrected P-value is quite 
conservative, since the tested markers are not independent (there is LD between 
markers within same genomic area) as they are assumed to be. Publication bias is a 
problem, since the positive association findings are published more easily than the 
negative ones. 
 
Genome wide association studies 
The availability of the sequence of the whole human genome (Lander et al 2001; 
Venter et al 2001) and the development of genotyping techniques made it possible to 
genotype thousands of SNPs throughout the whole genome with a reasonable 
amount of money and effort. These genome wide association (GWA) studies have 
taken the field of complex disease genetics to a new level. Now researchers do not 
need a priori hypotheses when conducting association analyses, but the association 
analyses can be done at the whole genome scale at once. The amount of SNPs in the 
GWA platforms range from 500,000 to up to 2 million SNPs, and this amount of 
common variants are estimated to capture about 90 % of the total genetic variation 
in the population (Lander 2011). The problems with this method are partly the same 
as in candidate gene studies. Because the susceptibility genes effect sizes are small 
in complex disorders of psychiatric genetics (1.12-1.20), the required amount of 
genotyped individuals to obtain genome-wide significant association is estimated to 
be as high as 8,000 – 20,000 (Cichon et al 2009). The multiple testing problem of 
GWA studies are dealt with through the agreement that the significance level is 
5x10-8, which is equivalent to a Bonferroni correction of one million tests.  
 
Meta analyses 
Since there are studies made in different populations with both positive and negative 
association results, meta-analyses are used to verify the significance of the results in 
combined analyses of all data sets available to achieve large sample size for 
statistical analyses(Pearson 1904). The meta-analyses can be performed either by 
using statistical data from all of the different single studies, or by combining all the 
original genotypes and data from single studies. The latter is more efficient (de 
Bakker et al 2008), but harder to achieve. The weakness of meta-analyses is the 
combination of genetic data of distinct populations, thus population stratification 
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skews the results. In psychiatric genetics, the wide variety of exact phenotypes used 
in different studies is also a problem that might falsify the results.  
2.3 Genetics of mood disorder 
2.3.1 Linkage findings 
The linkage peaks of mood disorder are spread all over the genome and also contain 
few replications and some shared linkage peaks for MDD and BD. Figure 1 
summarizes the genome wide significant linkage findings of both MDD and BD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Genome wide significant linkage findings of MDD and BD. The figure is 
adapted with permission  from Craddock and Forty (Craddock and Forty 2006) with 
modifications and updating.  
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L i n k a g e  o f  m a j o r  d e p r e s s i v e  d i s o r d e r 
Only few genome-wide linkage studies of MDD have been performed with a 
sufficient number of affected individuals, i.e. over 100 per study, by the end of May 
2012 (Abkevich et al 2003; Breen et al 2011; Camp et al 2005; Holmans et al 2007; 
Holmans et al 2004; Kuo et al 2010; McGuffin et al 2005; Middeldorp et al 2009; 
Nurnberger et al 2001; Pergadia et al 2011; Schol-Gelok et al 2010; Zubenko et al 
2003). Their findings are not consistent with each other and the linkage peaks are 
spread throughout the genome. In the first linkage study, the collected families 
contained individuals affected for both MDD and alcoholism (Nurnberger et al 
2001). The strongest linkage peak was gained with phenotype MDD or alcoholism 
and it was located in chromosome 1. The best linkage peak for depression only was 
located in chromosome 7. Holmans described linkage peak in the 15q25.3-26.2 in an 
initial analysis of 297 families (Holmans et al 2004) and when they expanded it to 
359 families, the linkage peak of 15q was further supported and also suggestive 
evidence of linkage was observed in chromosomes 8p and 17p (Holmans et al 2007). 
A study made in a sample of 81 families containing early-onset r-MDD cases 
(Zubenko et al 2003) contains many confusing points, like the use of many 
covariates in the analyses, so the comparison of the results to other studies is highly 
difficult, as summarized in the review article of MDD (Levinson 2006). The 
highlighted result from this study is the linkage peak in chromosome 2 near the 
CREB1 gene.  
Studies conducted in large UTAH pedigrees (Abkevich et al 2003; Camp et al 2005) 
found linkage in different areas depending on the selection of families and 
phenotype. In Abkevich (Abkevich et al 2003), large pedigrees (N=110) were 
genotyped and the linkage was analyzed against depressive phenotype containing 
both recurrent (N=784) and single episode MDD (N=161) as well as BD (N=162) 
cases. This study revealed strongest linkage on chromosome 12q22-12q23.2, in the 
same area that has linkage to BD (Cassidy et al 2007; Curtis et al 2003; Ewald et al 
2002; McInnis et al 2003a; Morissette et al 1999; Shink et al 2005b). Camp et al 
selected only families containing at least three r-MDD with early onset (before year 
30) excluding BD cases. They also did the analyses combining the anxiety disorder 
cases. The strongest linkage findings were on chromosomes 3centr, 7p, and 18q. In 
addition, 18q is a highly replicated linkage finding in BD (Coon et al 1996; Detera-
Wadleigh et al 1997; Fallin et al 2004; Freimer et al 1996; Garner et al 2001; 
McInnis et al 2003b; Schulze et al 2003; Tomas et al 2006).  
McGuffin (McGuffin et al 2005) used 497 affected sibling pairs and observed 
linkage on chromosomes 1p36, 12q23.3-q24.11, and 13q31.1-q31.3. The 12q 
linkage finding is a replication (Abkevich et al 2003), and as previously mentioned, 
there are multiple linkage findings for BD in this chromosomal area as well. 
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In a study of Dutch and Australian pedigrees, strongest linkage was gained on 
chromosomes 2, 8, and 17. The linkage of chromosome 17 was near highly studied 
candidate gene of SLC6A4 (Middeldorp et al 2009), but the association analyses of 
promoter length polymorphism of SLC6A4 did not reveal association with 
depression in either population (Gillespie et al 2005; Middeldorp et al 2007). 
In study by Schol-Gelok et al, the phenotype of depression was defined by 
depression subscale of the Hospital Anxiety Depression Scale (HADS-D) and the 
Center for Epidemiologic Studies Depression Rating Scale (CES-D), so they use the 
symptoms of depression, not the diagnosis of depression, in the definition. They 
found significant linkage on chromosomes 2p16.1-15 and suggestive linkage on 
chromosomes 5p15.33, 11q25, and 19p13.3 (Schol-Gelok et al 2010). Kuo et al. had 
families ascertained for alcohol dependence families collected from Ireland and used 
both alcohol dependence and MDD as a phenotype in their analyses. This study did 
not find genome-wide significant linkage, the strongest linkage peaks were located 
in the chromosome 4q32.3 (Kuo et al 2010).  
Two of the latest linkage studies of MDD revealed linkage on same chromosomal 
area: 3p25-26 (Breen et al 2011; Pergadia et al 2011). In Breen et al. the linkage was 
gained with the phenotype of r-MDD with sibling pairs of European origin (N=971). 
Pergadia et al. had heavy smokers’ families collected from Australia and Finland 
and they found the linkage with the phenotype of MDD in the Australian sample.  
 
L i n k a g e  s t u d i e s  o f  b i p o l a r  d i s o r d e r 
Linkage peaks of BD are spread all over the genome, there are linkage findings in 
every single chromosome with multiple hits within each chromosome (most detailed 
summarized in Serretti & Mandelli (Serretti and Mandelli 2008). Genome wide 
linkage studies of BD have been carried out since the beginning of the 90s, and until 
2009 there were over 40 genome-wide linkage studies done (Barnett and Smoller 
2009). After 2009, at least 7 linkage studies have been published, so the total 
amount of genome-wide linkage studies of BD is around 50. There are also three 
published meta-analyses that give distinct results (Badner and Gershon 2002; 
McQueen et al 2005; Segurado et al 2003). The original linkage studies selected to 
the meta-analyses are partly overlapping, but the linkage findings in these meta-
analyses differ completely. The first meta-analysis used seven studies and found 
strongest evidence for linkage on 13q and 22q (Badner and Gershon 2002). The 
largest meta-analysis used 18 studies, but did not find genome-wide significant 
linkage, although modest linkage was observed on chromosomal regions 9p22.3-21-
1, 10q11.21-22.1, and 14q24.1-23.12. The latest meta-analysis used a different 
approach and combined original data from 11 studies and analyzed it directly 
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(McQueen et al 2005). They described genome-wide significant linkage on 
chromosomes 6q21-25 and 8q24. Thus, the traditional genomic approach does not 
seem to have shed the light on the genetic susceptibility background of BD either.   
2.3.2 Candidate gene findings 
The selection of candidate genes for association studies of mood disorders are based 
either on previous linkage findings and/or sophisticated hypotheses of functional 
genes that could potentially affect the susceptibility of mood disorders. The older 
ones are mainly based on the relevance of the function of the gene, but more recent 
candidate genes are based on positional cloning, like in the case of DAOA and 
P2RX7. There are numbers of potential candidate genes for both MDD and BD and 
they are partly overlapping and shared also with other psychiatric disorders such as 
schizophrenia and anxiety disorder. Table 3 summarizes the previous association 
findings with mood disorder and related phenotypes of the candidate genes 
genotyped and analyzed in this thesis.  
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As expected, there is no single certain susceptibility gene for MDD showing 
association in every sample studied. The most studied candidate genes are related to 
monoamine (serotonin or dopamine) transmission and neuroprotection (Levinson 
2006; Lohoff 2010), and in every gene mention, there are positive association 
findings with both MDD and BD (see Table 3). 
 
Serotonergic genes 
One of the most promising systems that are hypothesized to be involved in the 
susceptibility to MDD is serotonergic transmission, since many antidepressants act 
on this system. The most highly studied candidate gene of this system is serotonin 
transporter (SLC6A4) and especially its 44-bp repeat polymorphism in the promoter 
region (HTTLPR), which is also shown to be a functional variant affecting SLC6A4 
expression levels (Lesch et al 1996). The short allele of HTTLPR has been 
associated with MDD in many studies (Table 3). Two meta-analyses have revealed 
evidence of short allele association with MDD (Furlong et al 1998; Lopez-Leon et al 
2008), although three meta-analyses do not support the evidence of association 
(Anguelova et al 2003; Lasky-Su et al 2005; Risch et al 2009). This same 
polymorphism is connected to the vulnerability of environmental factors, i.e. it has 
been shown to increase the risk of developing MDD in response to stressful life 
events (Caspi et al 2003). There are both positive and negative replication of this 
gene environment interaction (GxE) association with MDD (reviewed in (Uher and 
McGuffin 2010)). There are three meta-analyses done this far, and two of them do 
not support this GxE significance in MDD (Munafo et al 2009; Risch et al 2009), 
but the latest one found strong support for the HTTLPR and stress interaction behind 
MDD susceptibility (Karg et al 2011). One recent study dissected the stressful life-
events to childhood sexual abuse and adulthood stressors, and gained synergetic 
environmental and genetic interaction that increased the risk to develop MDD 
(Grabe et al 2012). Thus, the genetic and environmental architecture behind mood 
disorders susceptibility are highly complex.  
Widely studied serotonergic genes also include tryptophan hydroxylase 1 and 2 
(TPH1 and TPH2) (rate limiting enzymes of serotonin synthesis). TPH2 was found 
in 2003, when it was noticed that it is a predominant isoform in the brain, while the 
other one is expressed mainly in peripheral tissues (Walther and Bader 2003). The 
brain specific TPH2 gene was shortly linked to MDD by association analysis (Zill et 
al 2004a), and this was later replicated (Tsai et al 2009; Van Den Bogaert et al 2006) 
and positive association was gained also for BD (see Table 3). This gene is also 
located in the replicated linkage area of 2q.  
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Monoamine oxidase A (MAOA) gene encodes a protein that degrades monoamines, 
such as serotonin. A widely studied variable number tandem repeat (VNTR) variant 
in the promoter area of MAOA is associated both with MDD and BD, as well as 
many related phenotypes (Table 3). In recent meta-analyses, some evidence of 
association with both MDD and BD were found (Fan et al 2010), so it is 
hypothesized to be potential common candidate gene for mood disorders. 
 
Brain derived neurotrophic factor 
Brain derived neurotrophic factor (BDNF) is a widely studied candidate gene, both 
for MDD and BD. Its function makes it a very potential susceptibility gene for mood 
disorders since it regulates neurogenesis (Huang and Reichardt 2001) and mediates 
neuronal plasticity (Thoenen 1995). There are many arguments that support the role 
of BDNF behind MDD. Its expression in brain was first shown to be altered by anti-
depressant treatment in 1995, when it was shown that both chronic anti-depressant 
drugs and electroconvulsive seizure (ECS) treatments increase the expression of 
BDNF in different parts of the rat brain (Nibuya et al 1995). Its expression is 
decreased by stress (Smith et al 1995) and this reduction is restored by anti-
depressant treatments (Nibuya et al 1995). The effect of the stress is located mainly 
to the hippocampus, a brain area that is known to be relevant in depression and 
emotionality in general (Duman 2004; Groves 2007). Stress promotes cellular death 
and atrophy, and the same is seen in MDD patients that have shown to have smaller 
hippocampal volume compared to controls (Sheline et al 1996). The simplified 
model of stress and antidepressant effect to the BDNF function and mood is 
illustrated in Figure 2 (Groves 2007). The delayed antidepressant effect on mood has 
also given rise to the theory that brain structure and plasticity dysfunction is the 
leading cause of depression, and it is a BDNF recovery and its effects on brain 
plasticity that leads to the antidepressant effects of medication. Recent meta-analysis 
of plasma BDNF levels have shown that they are dependent on the state of disease, 
i.e. the levels are decreased in both depression and mania, but not in euthymia when 
compared to controls (Fernandes et al 2011). Therefore, there is a wealth of 
biological evidence that BDNF plays a major role in depression and mood disorders.  
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Figure 2. Model of stress and antidepressant effect on BDNF function in 
hippocampus. TrkB is a synonym for NTRK2, receptor of BDNF. Figure adapted 
from review article of Groves with permission (Groves 2007).  
 
The most studied genetic variant within the BDNF gene is rs6263, a functional 
variant that changes amino acid valine to methionine (val66met). The first positive 
association findings of this val66met variant and BD were made in 2002 (Neves-
Pereira et al 2002; Sklar et al 2002), and after that there have been positive 
replications for both MDD and BD (see Table 3). The meta-analysis of val66met 
and MDD found supporting evidence of BDNF association with MDD among males 
(Verhagen et al 2010), but the meta-analyses of BD studies did not find evidence for 
association (Gratacos et al 2007; Kanazawa et al 2007) 
The activation of BDNF receptor, NTRK2, is known to mediate the effects of BDNF 
in the cell, i.e. the plasticity function (Castren and Rantamaki 2010). Thus, the 
NTRK2 gene is also a good candidate gene for MDD and there are positive 
association findings for both MDD and BD, as well as other common co morbid 
disorders of mood disorders (see Table 3). CREB1 is also a potential candidate gene, 
because it enhances the transcription of BDNF via a regulatory loop with BDNF 
(Castren 2004). It regulates the transcription of BDNF target genes in cells after 
NTRK2 activation (Figure 3).    
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Figure 3. Simplified model of BDNF action in the cell after binding to the receptor 
NTRK2. Star represents the BDNF and the cell membrane receptor is NTRK2. 
Adapted from Autry and Monteggia with permission (Autry and Monteggia 2012). 
 
A recent sophisticated study has shown that many environmental factors known to 
associate with MDD (such as smoking, age, alcohol abuse), together with genetic 
vulnerability genes (such as BDNF), affect disease susceptibility (Wong et al 2012). 
The interaction of post-traumatic stress and val66met polymorphism of BDNF has 
also been shown to increase the risk for MDD (Rakofsky et al 2012). The BDNF-
CREB1-NTRK2 pathway, together with cognitive and neural intermediate 
phenotypes, has been shown to increase the risk for depression (Juhasz et al 2011). 
 
Meta-analysis and large scale replication 
One large meta-analysis has been performed in a large collaborative sample where 
replication of the candidate gene association results of MDD has been attempted 
(Lopez-Leon et al 2008) by examining all the polymorphisms that have been 
analysed in at least three separate studies. Twenty polymorphisms within 18 
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candidate genes were meta-analysed, these include four genes mention in Table 3 
(BDNF, COMT, SLC6A4, and MAOA). The only statistically significant association 
signal among these was gained for SLC6A4, the most studied HTTLR marker.   
When replication of the candidate gene results of MDD was attempted using GWAS 
data, only four genes out of the 57 analysed showed any evidence for association 
(Bosker et al 2011).  
 
B i p o l a r  d i s o r d e r 
The candidate genes of BD overlap widely with the MDD candidate genes - it could 
be said that all of the high potential candidate genes of MDD are also very good 
susceptibility candidate genes for BD, and positive association findings exist for 
both disorders (see Table 3). There is also broad overlap with BD and schizophrenia 
susceptibility genes, which is based on the phenotypic overlap of psychotic features, 
among other things.  
 
Purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7) 
The P2RX7 gene is located in linkage locus 12q23-24 of BD (Cassidy et al 2007; 
Curtis et al 2003; Ewald et al 2002; McInnis et al 2003a; Morissette et al 1999; 
Shink et al 2005b) and MDD (Abkevich et al 2003; McGuffin et al 2005). The 
linkage area was further characterized by denser microsatellite genotyping (Shink et 
al 2005a) and later SNP association studies found that non-synonymous variant 
rs2230912, also known as Gln460Arg, was most strongly associated with BD 
(Barden et al 2006) and MDD (Lucae et al 2006). Later association studies have 
found positive association findings for BD (McQuillin et al 2009), depressive 
(Hejjas et al 2009; Nagy et al 2008) and BD symptoms (Backlund et al 2011), and 
anxiety (Erhardt et al 2007), although association studies conducted in large samples 
have not replicated the association findings for MDD nor BD (Green et al 2009; 
Grigoroiu-Serbanescu et al 2009).  
P2RX7 gene encodes a ligand-cated calcium channel that is activated by ATP. It is 
expressed in a wide variety of tissues and cell types such as antigen presenting 
immune cells, bone, epidermal cells, and brain. In brain tissue, it has shown to be 
expressed in astrocytes, microglia cells, and in neurons, and its expression is located 
in various brain regions, including the hippocampus (Sperlagh et al 2006). The 
actions of activated P2RX7 receptor are dependent on ATP exposure time: with 
short exposure time, calcium channels open and signal transduction, depending on 
the cell type, proceeds; but with a long exposure time, large pores are formed on the 
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cell membrane and this eventually leads to the apoptosis of the cell. Thus, the 
receptor coded by this gene manifests many distinct functions both in brain and 
other tissues. There might be at least three different mechanisms in brain that lie 
behind the susceptibility to mood disorders. First, it has shown to promote the 
release of neurotransmitters, e.g. glutamate in hippocampus (Sperlagh et al 2002), 
thus linking this gene to one of the neurobiological theories (i.e. glutamergic 
dysfunction) behind mood disorders (Goodwin and Jamison 2007). Second, this 
gene function in inflammation reactions fits to the inflammation and stress induced 
theory of depression (Skaper et al 2010). Third, it has also shown to promote 
neurogenesis (Monif et al 2009) and cell death, thus acting as an important 
modulator of neuroprotection and neuroplasticity, both important factors behind 
mood disorders.  
 
D-amino acid oxidase activator locus in 13q34 
D-amino acid oxidase activator (DAOA) gene was found in 2002 when 
schizophrenia linkage locus 13q34 was tagged with dense SNP marker map and was 
found to contain two genes: D-amino acid oxidase (DAO also known as G30) and 
DAOA (also known as G72) both associated with schizophrenia (Chumakov et al 
2002). Linkage peaks of BD are also evident in this area, and soon after the first 
publication, BD was also found to associate with these genes (Hattori et al 2003). 
Both positive (Table 3) and negative association studies of BD were later published. 
The meta-analyses found significant association both with schizophrenia and BD, 
although the associating variants and areas were different between these two 
disorders (Detera-Wadleigh and McMahon 2006; Muller et al 2011).  
DAOA was found to activate DAO (Chumakov et al 2002), which in turn is a potent 
activator of glutamate receptor. The function of this gene, however, has remained 
vague and functional studies have been controversial (Kvajo et al 2008; Sacchi et al 
2011). Kvajo et al. found that one splicing variant of DAOA is located in the 
mitochondria and it seems to enhance the fragmentation of mitochondria and this 
way promotes the dendrite branching of neurons (Kvajo et al 2008). Functional 
studies of Sacchi et al. showed that DAOA seems to inactivate the DAO, not 
activate as it was previously believed, and thus protect cells from d-serine depletion 
i.e. it enhances glutamate receptor activity (Sacchi et al 2011). Recent data showed 
that genetic variation within DAOA has an effect on the dopamine turnover in the 
healthy brain (Andreou et al 2012), thus confirming the DAOA function as DAO 
regulator. Regardless of the real function(/s) of this gene, it is an interesting gene 
concerning brain function since it has evolved rapidly in evolution, the open reading 
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frame of human is twice as long as that of the chimpanzee homologue (Chumakov et 
al 2002), thus implying that it has an important role in human evolution.  
 
Other psychosis related candidate genes 
There are plenty of other candidate genes that were initially discovered in 
schizophrenia studies, but afterward also linked to BD. These include DISC1 that 
was first found in Scottish pedigree, where translocation containing this gene co-
segregated with major psychiatric illness such as Schizophrenia, BD, and r-MDD (St 
Clair et al 1990). There are positive association studies with mood disorders (Table 
3), although allelic heterogeneity is evident and negative reports also exist.  
Three mainly schizophrenia candidate genes have also gained interest in BD. 
Neuregulin 1 (NRG1) is a strong candidate gene for schizophrenia (Munafo et al 
2008; Stefansson et al 2002), but it has also associated with BD (Green et al 2005; 
Thomson et al 2007), thus it is suggested to be a common susceptibility gene for BD 
and schizophrenia (Walker et al 2010). Dystrobrevin binding protein 1 (DTNBP1) 
was identified as a schizophrenia candidate gene by systematic linkage 
disequilibrium mapping of a previously found linkage region 6p (Straub et al 2002). 
Both negative and positive association findings has been reported since, but only 
modest evidence of association in meta-analyses has been reported (Li and He 
2007). There are also positive association findings with BD (Breen et al 2006; 
Gaysina et al 2009; Joo et al 2007; Pae et al 2007). V-akt murine thymoma viral 
oncogene homolog 1 (AKT1) functions in actions such as neuronal migration and 
axon branching and it is associated with schizophrenia (Emamian et al 2004) as well 
as with BD (Toyota et al 2003). There is also recent evidence that this could be a 
common susceptibility gene for BD and schizophrenia (Karege et al 2012).   
 
Large scale meta-analyses of candidate gene studies of bipolar disorder 
Recent meta-analysis included 487 studies and 33 polymorphisms within 18 genes 
to the analysis and the GWA data were also included in the analyses (Seifuddin et al 
2012). None of the genes exceeded statistically significant P-values, although 
polymorphisms within BDNF, DAOA, DRD4, and TPH1 showed nominally 
significant associations.  
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2.3.3 Genome wide association studies 
In the field of psychiatric genetics, many have been disappointed with the outcome 
of GWA approaches, since they have not revealed any definite predisposing genetic 
factors, although they have brought totally new susceptibility candidates that have 
not even been considered in previous a priori studies. 
 
G W A S  o f  m a j o r  d e p r e s s i v e  d i s o r d e r 
Altogether seven GWA studies of MDD have been published up to the end of May 
2012 (Lewis et al 2010; Muglia et al 2010; Rietschel et al 2010; Shi et al 2011; Shyn 
et al 2011; Sullivan et al 2009; Wray et al 2012). In the first published GWA study, 
1738 MDD cases were genotyped, but no genome-wide significant results were 
obtained, although 11 of the top 200 association signals were located at the gene 
piccolo (PCLO) (Sullivan et al 2009). The replication sample (N=6079) did not 
confirm the results, although authors claimed that the reason was a heterogeneous 
sample. Recent replication efforts have support the role of PCLO in the etiology of 
MDD (Hek et al 2010; Minelli et al 2012), especially among females (Aragam et al 
2011).  
There have been no genome-wide significant results in any of the subsequent GWA 
studies, although some interesting potential new candidate genes emerged that 
warrant mention here. There was suggestive evidence of association with two SNPs 
in BICC1 gene (P<10-6) by Lewis (Lewis et al 2010), although the signals were not 
strengthened when the signal was meta-analyzed with previous GWA data (Muglia 
et al 2010). In a study by Rietschel et al., nominal association was found with SNPs 
located upstream of the carboxypeptidase M (CPM) and regulatory area of Homer 1 
gene (Rietschel et al 2010). Homer 1 gene seems to be of interest, taking into 
account the MRI studies that describe the influence that a variant of this gene has on 
prefrontal activity during executive cognition and anticipation of reward.  
In a GWA study conducted by Shi et al., there was evidence of association with a 
SNP in the mRNA detected in human brain tissue (BC053410) and approximately 
75 kb upstream of DSEL, and when the data was combined to previous GWAS 
genotypes, association was seen within the SP4 gene, a brain-specific transcription 
factor gene (Shi et al 2011).  
When completing a meta-analysis with previous GWA data (Shi et al 2011; Sullivan 
et al 2009) Shyn found suggestive evidence of association in three different genomic 
areas:  intronic SNPs in ATP6V1B2 (P = 6.78 × 10−7), SP4 (P =7.68 × 10−7), and 
GRM7 (P = 1.11 × 10−6) (Shyn et al 2011). Wray also performed meta-analyses 
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with previous GWAS data (Lewis et al 2010; Sullivan et al 2009) and found 
suggestive evidence of association with SNPs within adenylate cyclase 3 (ADCY3, 
2p23.3) and galanin (GAL, 11q13.3) (Wray et al 2012).  
Two meta-analyses done that included both MDD and BD studies, also explored the 
genome-wide associations for mood disorders (Liu et al 2011; McMahon et al 
2010). In a study by McMahon (McMahon et al 2010), four GWA studies with 
European ancestry were included in the analyses; one MDD (Boomsma et al 2008) 
and three BD studies (Sklar et al 2008; Smith et al 2009; WTCCC 2007). This study 
found shared genome-wide significant association of MDD and BD that was located 
in the 3p21.1 with smallest P-value gained with the SNP rs2251219. The associating 
area contains many genes and the LD between markers is strong, thus the exact 
position of a functional variant is impossible to catch by association approach. The 
study by Liu (Liu et al 2011) combined MDD (Sullivan et al 2009) and BD (Ferreira 
et al 2008) GWA data. This study supported the role of CACNA1C in the aetiology 
of mood disorder. 
 
G W A S  o f   b i p o l a r   d i s o r d e r  
All GWAS performed for BD thus far (May 2012) are summarized in Table 4. The 
main findings of these studies are not consistent with each other, although there are 
replication studies made in smaller samples. The association signal exceeds genome-
wide significance level (P < 5 x 10-8) in only one study (Baum et al 2008a), where 
SNP in DGKH associated with BD with the P-value of 1.5 x 10-8 (OR = 1.59). Many 
of the studies also completed meta-analyses (Table 4) combining previous GWAS 
data to the analyses. In these additional meta-analyses, some studies exceeded the 
genome-wide significance level (Ferreira et al 2008). A study by Ferreira (Ferreira et 
al 2008) used two previous GWAS data sets in the meta-analysis (Sklar et al 2008; 
WTCCC 2007) reaching altogether 4387 cases. In this study, two SNPs within 
ANK3 gene gave genome-wide significant association signals (P = 9.1 × 10-9, OR 
1.450 and P = 1.3 × 10-8, OR 1.395).  
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Table 4. Genome wide association studies of BD completed by the end of May 2012. 
Study Population Number 
of p<10-6 
Associating 
areas/genes 
Meta-
analysis 
(WTCCC 2007) European 
(2000) 
1 16p12 No 
(Baum et al 2008a)a European 
(461+772) 
1b DGKH No 
(Sklar et al 2008) European 
(1461) 
2 MYO5B, TSPAN8 No 
(Ferreira et al 2008) European 
(2365) 
0  Yes 
(Hattori et al 2009) Japanese 
(107+395) 
0  No 
(Scott et al 2009) European 
(2076) 
2 CPS1, NEK7 or 
ATP6V1G3 
Yes 
(Smith et al 2009) European 
(1001), 
African (345) 
0  No 
(Lee et al 2011a) Chinese 
(1000) 
1 Specificity protein 8 
(SP8) 
No 
(Djurovic et al 2010) Scandinavian 
(194+435) 
0  No 
(Cichon et al 2011) European 
(682+2411) 
2 NCAN, MAD1L1, Yes 
(Smith et al 2011b) European 
(1190+1001) 
2 NEK7; MGAT4A Yes 
(Yosifova et al 2011) Bulgarian 
(376+122) 
0  No 
a Study used a pooled DNA sample in the initial screening 
b P-value exceeded genome-wide significance level 
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A few meta-analyses have also been performed from the GWA data thus far. Sklar 
(Sklar et al 2011) combined six GWA studies (Djurovic et al 2010; Ferreira et al 
2008; Scott et al 2009; Sklar et al 2008; Smith et al 2009; WTCCC 2007) 
incorporating altogether 7481 BD cases to the analyses. When the initial data was 
combined to the replication sample (N = 11 974), genome-wide significant 
association signal was gained for CACNA1C (OR=1.14) and ODZ4 (OR=0.88) 
genes.  
Overall, genome-wide significant findings are achieved with huge sample sizes and 
the odds ratios have been small, thus the effects of the variants to the disease 
susceptibility are only modest.  
2.3.4 Other genetic avenues 
Large GWA data sets have provided new tools for genetic analyses, such as enabling 
the study of copy number variants (CNV) in a genome-wide manner. There is 
evidence that rare singleton deletions could be important factors behind BD (Zhang 
et al 2009a), although a more recent study reported opposite results showing no 
excess of CNVs in BD cases compared to controls (Grozeva et al 2010). Hence, 
although there are studies showing specific alterations among CNVs in BD cases 
versus controls (Lachman et al 2007; Wilson et al 2006), the overall differences in 
the number of CNVs continues to be unresolved.  
Gene-gene interactions have been thought to play an important role in the aetiology 
of mood disorders, but the statistical analyses are highly complex and demanding. 
There are few genome wide interaction analyses done in BD (Abou Jamra et al 
2007; Fullerton et al 2012) which are based on linkage studies in large families. The 
best results that exceeded statistical significance after permutations of these studies 
were 2q22-q24 - 6q23-q24 and 2q22-q24 - 15q26 (Abou Jamra et al 2007) and 
11q23-25–2p15-12, 4q32-35–1p36, 12q23-24–4p16-15, and 20q13–9q21-22 
(Fullerton et al 2012).  
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3 AIMS OF THE STUDY 
The principle aim of this investigation was to characterize the genetic background of 
mood disorders and their endophenotypes in Finnish mood disorder samples, a 
bipolar family sample and a case-control sample comprising three clinical cohorts. A 
candidate gene approach was used in studies I, II, and III. In studies IV and V the 
results from previous GWA studies of bipolar disorder were exploited in an attempt 
to replicate their findings in the Finnish bipolar family sample. 
These aims in detail were: 
1) To study if so called classical candidate genes of mood disorders explain genetic 
liability to mood disorders in the bipolar family sample (I) and in the clinical cohorts 
(II). 
2) To survey if BD has shared genetic background with MD (II) or with 
schizophrenia (III). 
3) To investigate if variants identified by previous GWA studies have impact on 
genetic aetiology of mood disorders in the Finnish bipolar family sample (IV and 
V). 
4) To investigate if some of the potential endophenotypes of mood disorders 
(cognitive functions, circadian preference and seasonal pattern of mood) mediate the 
genetic effect of the risk variants (I, III and V). 
5) To further dissect the effect of the genetic risk variants on comorbidities for mood 
disorders and on clinical outcome of patients (II). 
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4 MATERIALS AND METHODS 
4.1 Study samples 
Two distinct sample sets were used in this thesis. The first one is a bipolar family 
sample that contains altogether 180 families with 723 genotyped individuals from 
the whole of Finland (I, III-V). The second one comprises three clinical cohorts for 
mood disorders, collected from the metropolitan area of Southern Finland (II).  
4.1.1 Bipolar family sample 
Bipolar family sample was collected by exploiting the National Hospital Discharge 
Register to identify all individuals who were hospitalized for BDI between 1969 and 
1991 in Finland. The register indexes all primary diagnoses for inpatients stays at 
public and private hospitals. The collection is delimited to individuals who were 
born between 1940 and 1969. Before the year 1987, the diagnoses were made using 
the International Classification of Diseases, version 8 (ICD-8) (WHO 1967). After 
1987 the diagnoses were made according to the criteria of the Diagnostic and 
Statistical Manual of Mental Disorders, revised third edition (DSM-III-R) 
(American Psychiatric Association 1987). Two psychiatrists also made independent 
diagnoses using all available case notes according to DSM-IV diagnostic criteria 
(American Psychiatric Association 1994) for BDI. Information on first-degree 
relatives was assembled from the National Population Register. All available records 
from hospitals, clinics, general practitioners, reports from medico-legal experts and 
various other sources were examined to provide diagnostic information for the 
relatives of the probands.  
In addition, eight bipolar families were identified among a schizophrenia family 
sample, which had been collected using the same registers (Hovatta et al 1999). 
These eight families contain family members with schizoaffective bipolar type 
disorder. The remaining individuals are from BP twin sample where 32 families 
were recruited. The Finnish twin cohorts were used to identify twins in which at 
least one was affected with BD (Kieseppa et al 2004). In these subsamples the 
diagnoses were made in the same manner as described earlier. 
 
The diagnostic categories that were used in this study were the bipolar spectrum and 
the psychotic disorder groups. The bipolar spectrum disorder patient group (n=227) 
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covered: BDI (n=214), BDII (n=5), BD-not-otherwise-specified (BD-NOS) (n=6), 
and cyclothymia (n=2) cases. The psychotic disorder group includes only 
individuals with the presence of life-time psychotic symptoms (n=251). This 
category included patients with the diagnoses of BDI (with intermittent psychotic 
features) (n=162), schizoaffective disorder (SA) (n=51), psychotic depression 
(n=15), schizophrenia (n=14), and psychosis NOS (n=9). There was an overlap of 
162 individuals between the two categories.  
 
Familial subsample was identified by selecting only those families that had at least 
two affected individuals in the pedigree. Familiality was seen in 118 families (66 % 
of all families) with 543 genotyped individuals, for detailed information see Table 5. 
 
Table 5. Description of the bipolar family sample.  
 Female Male Total Familial 
Affected 170 192 362 258 
Bipolar spectrum disorder 109 118 227 173 
Psychotic disorders 117 134 251 212 
In both categories 83 79 162 127 
Other mental disorders 28 36 64 45 
Unaffected 208 153 361 241 
Neuropsychological subsample 82 77 159 155 
Circadian/Seasonal subsample 64 63 127 127 
Total genotyped 378 345 723 544 
 
Neuropsychological tests 
Neuropsychological test results were used in the genetic analyses in studies I, III, 
and V. Neuropsychological test pattern was performed for 159 individuals from 65 
families. The test pattern used in this study includes subtests from the Wechsler 
Adult Intelligence Scale – Revised (WAIS-R) (Wechsler 1981) and the Wechsler 
Memory Scale-Revised (WMS-R) (Wechsler 1987), The California Verbal Learning 
Test (CVLT) (Delis 1987), the interference score from the Stroop Color and Word 
Test (Golden 1978), and the Controlled Oral Word Association Test (COWAT) 
(Benton 1989). The tests and the feature they assess are listed in Table 6.  
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Table 6. The neuropsychological tests used in the genetic analyses (Studies I, III, 
and V). 
Neuropsychological test Assessed feature 
WAIS-R General intellectual functioning 
  Vocabulary   General ability 
  Similarities   Verbal abstraction 
  Digit Symbol   Psychomotor speed 
  Block Design   Visuospatial ability 
WMS-R Attention and memory 
  Digit Span forward   Auditory attention 
  Digit Span backward   Verbal working memory 
  Visual Span forward   Visual attention 
  Visual Span backward   Visual working memory 
  Logical Memory I   Immediate verbal memory 
  Logical Memory II   Delayed verbal memory 
  Visual Reproduction I   Immediate visual memory 
  Visual Reproduction I   Delayed visual memory 
CVLT Verbal learning and memory 
  Free short delay recall  
  Free long delay recall  
  Recognition memory  
  Retention  
Stroop Color and Word Test  
  Interference score   Selective attention and executive functioning 
COWAT   Semantic and Phonemic fluency 
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Circadian preference and seasonality 
Two different questionnaire’s results were exploited in study V: the results from 
Quantitative items of the Horne-Östberg Morningness-Eveningness Questionnaire 
(MEQ) (Horne and Ostberg 1976); and six items from of seasonal variation in mood 
and behavior (Global seasonality score, GSS) from the Seasonal Pattern Assessment 
Questionnaire (SPAQ) (Rosenthal et al 1987), performed on 127 individuals from 37 
families. MEQ test pattern assessed the circadian preference of daily activities like 
sleep, work, and physical activity. The items and factors of MEQ used in the genetic 
analyses are summarized in Table 7. The MEQ factors were calculated by making 
the factor matrix using maximum likelihood principle, and the standard orthogonal 
varimax rotation was computed in order to examine the degree of correlation among 
factors using the RELIAB module of the Survo MM program, release 2 
(www.survo.fi/mm/english.html). GSS items used in the genetic analyses assess if 
there is a seasonal variation in 1) sleep duration, 2) social activity, 3) mood, 4) 
weight, 5) appetite, and 6) energy level.  
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Table 7. Quantitative items of the Horne-Östberg Morningness-Eveningness 
Questionnaire (MEQ). 
 
Item/Factor Question/content 
#1 "Considering only your own "feeling best" rhythm, at what time 
would you get up if you were entirely free to plan your day?" 
#2 "Considering only your own "feeling best" rhythm, at what time 
would you go to bed if you were entirely free to plan your 
evening?" 
#10 "At what time in the evening do you feel tired and as result in need 
of sleep?" 
#17 "Suppose that you can choose your own work hours. Assume that 
you worked a FIVE hour day (including breaks) and that your job 
was interesting and paid by results. Which FIVE CONSECUTIVE 
HOURS would you select?" 
#18 "At what time of the day do you think that you reach your "feeling 
best" peak?" 
SUM Sum score of all the 19 items (range=16-86) 
Factor 1 Factor loaded mainly by the items #9 "You have decided to engage 
in some physical exercise. A friend suggests that you do this one 
hour twice a week and the best time for him is between 7.0 - 8.0 
AM. Bearing in mind nothing else but your own "feeling best" 
rhythm How do you think you would perform ?", and #17 
Factor 2 Factor loaded mainly by the items #7 "During the first half-hour 
after having woken in the morning, how tired do you feel?, and #4 
"Assuming adequate environmental conditions, how easy do you 
find getting up in the mornings?" 
Factor 3 Factor loaded mainly by the items #15 "You have to do two hours 
of hard physical work. You are entirely free to plan your day and 
considering only your own "feeling best" rhythm which ONE of 
the following times would you choose?" 
Factor 4 Factor loaded mainly by the item #12 "If you went to bed at 11 pm 
at what level of tiredness would you be?" 
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4.1.2 Mood disorder cohort 
The sample used in study II was gathered from three separate but comparable 
clinical cohorts that all are collected from psychiatric in- and outpatients from the 
metropolitan area of southern Finland. Three cohorts are 1) the Jorvi Bipolar Study 
(JoBS) (Mantere et al 2004; Mantere et al 2008), 2) the Vantaa Depression Study 
(VDS) (Holma et al 2008; Melartin et al 2002), and 3) the Vantaa Primary Care 
Depression Study (PC-VDS) (Vuorilehto et al 2005; Vuorilehto et al 2009). All 
clinical cohorts are collected in collaboration with the Mood Disorder Research Unit 
of the Department of Mental Health and Alcohol Research Unit of the National 
Institute for Health and Welfare.  
Patient sampling was based on screening for BD (in JoBS), MDD (in VDS), and 
depressive disorders (in PC-VDS). The target groups were all psychiatric patients 
aged 18 (in JoBS) or 20 (VDS and PC-VDS) to 59 years and seeking treatment, 
referred to treatment, or already in treatment. In JoBS, the screening was based on 
the Mood Disorder Questionnaire and clinical suspicion of BD; in VDS to the 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN) and Scale for 
Suicide Ideation, and in the PC-VDS to the Primary care evaluation of mental 
disorders (PRIME-MD) and Structured clinical interview of DSM-IV axis I 
disorders, research version, patient edition with psychotic screen (SCID-I/P) by 
telephone interview. Those that were positively screened were diagnosed using 
DSM-IV diagnostic criteria. The numbers of the individuals in each cohort and the 
amount of BD and MDD individuals in the final Mood Disorder Cohort are 
described in Figure 4. 
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Figure 4. Description of Mood Disorder cohort and its composition from three 
clinical cohorts. 
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Most of the genotyped individuals were followed up: 95.5% of JoBS, 93.9 % of 
VDS, and 97.9 % of PC-VDS. The follow-up median duration was 19, 66, and 62 
months in JoBS, VDS, and PC-VDS, respectively. In follow-up patients were 
interviewed at 6 and 18 months, and at 5 years.  
The diagnostic phenotype used in this study was based on the diagnostic interviews. 
In addition to DSM-IV diagnoses of BD and MDD, co morbid lifetime anxiety 
disorder and alcohol dependence were used in the analyses, as well as incidence of 
psychotic symptoms or suicide attempts, age of onset, and time ill.  
4.1.3 Control sample 
In study II, a control sample of 1322 individuals was derived from the population-
based Health 2000 study of Finland (Pirkola et al 2005). The control sample 
included 708 females and 562 males with no depression or any other psychiatric 
disorder according to the Composite International Diagnostic Interview (CIDI). 
4.2 Laboratory methods and statistical analyses 
Table 8 summarized the laboratory methods and the statistical analyses utilized in 
this study. The methods are described in more detailed in original publications and 
below. 
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Table 8. The laboratory methods used in original publications. 
Method Reference Study 
Laboratory procedure   
DNA extraction  I-V 
Polymerase chain reaction (PCR)  (Kleppe et al 1971) I-V 
Agarose gel electrophoresis  I-V 
Allele-specific primer extension on 
microarrays 
(Pastinen et al 2000) 
III 
Sequenom hME reaction Sequenom, San Diego,CA,US I, III 
Sequenom iPLEXTM biochemistry Sequenom, San Diego,CA,US I,II,IV,V 
   
Electrophoresis, ABI377/3730 Applied Biosystems, Foster 
City, CA, US  
I, II 
Analysis program    
SNPSnapper  III 
Genemapper Applied Biosystems, Foster 
City, CA, US  
I, II 
Pedcheck (O'Connell and Weeks 1998) I,III-V 
Haploview (Barrett et al 2005) I-III 
PLINK (Purcell et al 2007) II 
HRR (Terwilliger and Ott 1992) III 
SPSS 14.0 SPSS Inc., Chicago, IL, US I-III 
FBAT (Horvath et al 2001) I,III-V 
R program www.R-project.org II 
QTDT (Abecasis et al 2000) I, III, V 
Statistical method   
ANOVA  III 
Logistic regression  II 
Pearson Chi-Square  I-V 
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4.2.1 Marker selection and genotyping 
SNP selection was made using public SNP database (dbSNP) (www.ncbi.nlm.gov) 
(studies I-III) and by taking advantage of the HapMap database to cover the 
haplotype-tagging SNPs using the cut-off values of 0.2 for minor allele frequency 
and 0.8 for coefficient of determination (r2) (I-II). In Studies IV and V, the SNP 
selection was based on previous GWA findings. The summary of genotyped genes 
and variants in Studies I-III are listed in table 9. 
 
Table 9. List of studied genes and the number of genotyped variants in studies I - 
III. 
 
Gene Location Number of 
genotyped variants 
Study 
AKT1 14q32.32 2 III 
BDNF 11p13 10/7a I, II 
COMT 22q11.21 2/11b II, III 
CREB1 2q34 9 I 
DAOA 13q34 11/13b II, III 
DISC1 1q42.1 6 II 
DTNBP1 6p22.3 14 III 
MAOA Xp11.3 5 II 
NRG1 8p12 11 III 
NTRK2 9q22.1 15/9a I, II 
P2RX7 12q24 10/8a I, II 
SLC6A4 17q11.2 9/8a I, II 
TPH2 12q21.1 15/9a I, II 
 
aNumber of variants genotyped in Study I/II 
bNumber of variants genotyped in Study II/III 
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Genotyping of COMT in Study III was performed by allele-specific primer 
extension method based on microarrays. Genotyping of other genes in Study III was 
performed by homogenous Mass Extension (hME) using the MassARRAY System. 
In Study I, genotyping was performed using both hME and Sequenom iPLEXTM 
biochemistry. In studies II, IV, and V, Sequenom iPLEXTM biochemistry was used 
for genotyping. Three microsatellite markers were genotyped in studies I and II, and 
the genotyping was performed by electrophoresing PCR amplified microsatellite 
markers on an ABI 3730 Automatic DNA sequencer (Applied Biosystems, Foster 
City, CA, USA) as described in Utge et al. (Utge et al 2009). 
As a quality check for the genotyping, there were duplicates in each sample plate, 
the family structure were checked by Pedcheck program (studies I, III-V) and 
deviation from Hardy-Weinberg equilibrium was tested by chi-square test for every 
marker.  
4.2.2 Statistical analyses 
The allelic association analyses were done by FBAT (studies I, IV, V), HRR (III), or 
PLINK (II). Haplotype analyses were made by FBAT (studies I and III) or PLINK 
(II). Quantitative traits were analyzed with the Quantitative Transmission 
Disequilibrium Test (QTDT) software package with the polygenic variance 
component option with total association model assuming no population stratification 
(studies I, III, V) or by a linear regression model using PLINK (II). In study II, the 
quantitative trait of time in illness (time ill) was analysed using logistic regression 
by R program.  
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5 RESULTS AND DISCUSSION 
5.1 Results of candidate gene studies (I-III) 
5.1.1 Candidate gene study of bipolar family sample (I) 
There are many potential susceptibility genes of BD and MDD. Here, those that 
seemed to carry the most potential and interest in the era before GWA studies were 
chosen, at the commencement of the study. This included genes related to neuronal 
plasticity (BDNF, NTRK2, and CREB1), serotonin neurotransmission (SLC6A4 and 
TPH2), and inflammation (P2RX7). These six functional candidate genes were 
genotyped and analysed in the Finnish bipolar family sample. The genotyped 
variants were analysed both against the disease status (against bipolar spectrum 
disorder and against presence of life-time psychotic symptoms) as well as against 
neuropsychological test results. 
The strongest evidence for association of BD spectrum disorder was gained for 
BDNF with familial subsample and for SLC6A4 among males (Table 10). The most 
studied BDNF variant rs6265 (Val66Met) associated with the familial BD spectrum 
with the P-value 0.016, valine being the risk allele. Three variants (rs3794808, 
rs140700, and rs6354) within SLC6A4 associated with BD spectrum disorder, 
strongest among males (P = 0.047, 0.007, and 0.023 respectively). There was also 
suggestive evidence for association with variant rs2230912 within P2RX7 gene, and 
also here the association signal was derived mainly from males (P = 0.038).  
Haplotype analyses revealed some new evidence of association with all the three 
genes that associated in the initial two-point analyses. In BDNF gene, the 5’ flanking 
region haplotype associated with bipolar spectrum disorder (rs1491850-rs1491851, 
T-C, P = 0.004). Within SLC6A4, the strongest haplotype association signal came 
with the haplotype rs140700-rs6354 (T-G, P = 0.017), and the signal strengthened 
slightly when the analyses were made among males (P = 0.004). Several haplotypes 
within P2RX7 showed suggestive association signal. The strongest signal was 
gained with the haplotype rs208290-rs208294-rs208298-rs504677 (G-T-G-C, P = 
0.006).  
In BDNF, the same variants that associated with bipolar spectrum disorder, also 
associated with memory functions. The val66met associated with retention and 
rs1491850 with immediate verbal memory (P = 0.0087 and 0.0081, respectively). In 
val66met, the disease associating allele (valine) associated with better performance 
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in retention. In addition, the haplotype that associated with the disease also 
associated with retention (T-C of rs1491850-rs1491851; P=0.0004). The best 
association results of neuropsychological tests were gain with the P2RX7 variants 
rs504677 and rs1718119 that associated with the semantic fluency (P = 0.0001 and 
0.0010, respectively) (Table 10). The same haplotype that associated with the 
bipolar spectrum disorder, also associated both with semantic and phonemic fluency 
(P = 0.006 and 0.0003, respectively).  
 
Table 10. The association results of BDNF, SLC6A4 and P2RX7 variants with BD 
spectrum and neuropsychological test results showing evidence of association with 
dichotomized traits with P-value < 0.05 and with quantitative traits with P-value < 
0.001. 
  BD spectrum   Neuropsychiatric tests 
Variant All Familial Male Female 
Auditory 
attention 
(Digit Span 
Forward) 
Immediate 
verbal memory 
(Logical 
Memory I) Retention 
Semantic 
fluency  
BDNF 
rs6265 0.062 0.016 0.203 0.134 0.9546 0.5316 0.0087 0.7037 
rs7934165 0.277 0.408 0.967 0.124 0.8204 0.0189 0.0075 0.1382 
rs1491850 0.818 0.942 0.412 0.529 0.7781 0.0081 0.0152 0.0722 
rs1491851 0.032 0.075 0.433 0.022 0.9231 0.6521 0.2578 0.9783 
SLC6A4 
rs7224199 0.076 0.05 0.064 0.545 0.3687 0.0046 0.395 0.3624 
rs3794808 0.045 0.041 0.047 0.474 0.7564 0.0114 0.4284 0.4957 
rs140700 0.021 0.042 0.007 0.834 0.7383 0.1613 0.5242 0.2609 
rs6354 0.083 0.036 0.023 0.973 0.3055 0.1566 0.2261 0.5839 
P2RX7 
rs208290 0.755 0.64 0.623 0.935 0.0078 0.71 0.1894 0.6725 
rs504677 0.31 0.371 0.235 0.873 0.2468 0.3766 0.5308 0.0001 
rs1718119 0.399 0.483 0.342 0.874 0.1039 0.7848 0.3148 0.0010 
rs2230912 0.048 0.061 0.038 0.574   0.6253 0.2914 0.6941 0.0575 
 
 
The main result in this study was the replication of the BDNF functional variant 
val66met association with BD, even though the association signal is only modest 
taking the amount of tests done into account. Although previous studies of BDNF 
have been inconsistent and the meta-analyses have been negative (Gratacos et al 
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2007; Kanazawa et al 2007), there are family studies that have been more consistent 
showing association of BD with the valine allele (Liu et al 2008; Neves-Pereira et al 
2002; Sears et al 2011; Sklar et al 2002) like in this study. One case-control study 
also found association of valine allele with BDI and this study used only cases that 
had positive family history of affective disorders (Lohoff et al 2005), which might 
explain the contradictory results with the meta-analyses done. So it could be that the 
BDFN is associated with a specific type of BD, since it has been shown that there 
are plenty of clinical phenotypes that are clustered to the families, like age of onset, 
life time severity of mania, and presence of psychosis (summarized in Box 2 in 
Craddock & Sklar (Craddock and Sklar 2009)).  
Some encouraging support was seen in the results for the hypothesis that the 
neuropsychological test data could be a good endophenotype for BD. The risk allele 
of functional variant val66met of BDNF associated with better memory function, 
which is in line with previous studies where valine allele has been connected with 
different aspects of better performance in memory function (Egan et al 2003; 
Goldberg et al 2008; Hariri et al 2003; Ho et al 2006) as well as with better 
performance in executive function (Lu et al 2012). It has been shown that the valine 
allele increases depolarization-induced secretion of BDNF in brain (Egan et al 
2003), thus giving a hint about the mechanism that might be behind this 
neuropsychiatric association. Population genetics studies have shown that there is 
positive selection for haplotypes containing the valine allele in the val66met locus 
(Petryshen et al 2009), thus giving one explanation as to why BD has not vanished 
in evolution. It has not vanished, because the same allele that predisposes to the 
disease also gives fitness benefit to the risk allele carrier by enhancing memory and 
executive functions.  
The previous association of P2RX7 non-synonymous variant rs2230912 and mood 
disorder was replicated here (Barden et al 2006; Lucae et al 2006; McQuillin et al 
2008) (+study II) and this was an allelic replication. For the P2RX7 gene, the studies 
carried out in the large cohort samples have also been negative (Green et al 2009; 
Grigoroiu-Serbanescu et al 2009). This could be due to the fact that P2RX7 gene 
contains many functional variants, which potentially could dilute the association 
findings. This is also seen in our study, where both single variants and larger 
haplotype associated both with the disease and with potential endophenotypes, that 
is, executive functions. The associating variants span throughout the gene, the 
strongest haplotype association spans from the third to eighth intron and the 
replication variant is located in 14th exon.    
The P2RX7 results also demonstrate the value of using endophenotypes in genetic 
studies. It seems that the intermediate phenotype by which this gene affects disease 
susceptibility is different than in the case of BDNF. Here, the associating 
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endophenotype is executive function that has shown to be impaired in euthymic 
depressive patients (Paelecke-Habermann et al 2005), indicating that this gene might 
be specific to the depressive symptoms of BD. The depression specificity is further 
pointed out in study II, where the variants of this gene associate most strongly with 
familial MDD.   
5.1.2 Candidate gene study of mood disorder cohort (II) 
In study II, a shared genetic background of MDD and BD was sought in the sample 
comprising three clinical cohorts. Since the cohorts were also rich in data related to 
clinical course of mood disorders, the effect of the identified risk variants on the 
specific co morbidity or long-term clinical outcome was investigated. It was also 
hypothesized that the genetic loading of the risk alleles would be greater within the 
cases with a positive family history. The genes examined in II included BDNF, its 
receptor NTRK2, serotonin related genes SLC6A4 and TPH2, P2RX7, DAOA, 
COMT, DISC1, and MAOA.  
Altogether five out of nine studied genes revealed suggestive evidence of 
association with mood disorder. The strongest signal was gained with two 
nonsynonymous variants of P2RX7, rs208294/His155Tyr (His=C, Tyr=T) and 
rs2230912/Gln460Arg (Gln=A, Arg=G), in the whole sample (OR=1.26, p=0.003 
and OR=1.29, p=0.017, respectively) and specifically in patients with familial mood 
disorder (OR=1.35, p=0.0013, permutated p=0.064, and OR=1.44, p=0.0031, 
permutated p=0.173, respectively) (Table 11). The association signals vanished 
when cases without familial loading were analyzed (p=0.37 and p=0.80, 
respectively). The risk alleles were T/Tyr in the rs208294 and G/Arg in the 
rs2230912. Variants rs3794808, VNTR2i, and 5HTTLPR within SLC6A4 gene were 
suggestively associated with mood disorder in the whole sample (OR=0.82, p=0.01, 
OR=1.25, p=0.007, and OR=1.24, p=0.007, respectively) (Table 11). The 
associating alleles were 9R/10R in the VNTR2i variant and La in the 5HTTLPR 
variant. Nominal associations were also seen with NTRK2, BDNF, and DAOA 
variants. 
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Table 11. Summary of the best association signals (P-values) gained with variants 
within P2RX7 and SLC6A4 genes. 
  
Mood 
(All)  
Mood 
(Familial)  
MDD 
(All)  
MDD 
(Familial)   Anxiety  Alcoholism   
Time 
in 
illness 
P2RX7 
rs591874 0.0103 0.0026 0.0053 0.0030 0.0008 0.0056 0.5007 
rs208290 0.0706 0.0299 0.0507 0.0265 0.0182 0.1426 0.8006 
rs208294 0.0033 0.0007 0.0070 0.0023 0.0008 0.0007 0.0683 
rs2230912 0.0172 0.0007 0.0217 0.0019 0.0102 0.0016 0.0003 
SLC6A4 
rs3794808 0.0115 0.1686 0.0046 0.1012 0.0315 0.0399 0.4453 
intron2 0.0066 0.0079 0.0017 0.0056 0.0716 0.0514 0.0136 
5HTTLPR 0.0072  0.1396  0.0006  0.0686   0.0659  0.0166   0.4439 
 
 
Haplotype analyses did not bring any further information to the association findings 
of P2RX7 gene. In SLC6A4 gene, there was slightly stronger association signal with 
the haplotype spanning from the promoter region to second intron (5HTTLPR-
rs4451417-rs6354-VNTR2i haplotype La-C-T-9R/10R; OR=1.31, p=0.001, 
frequency in cases = 0.39, in controls = 0.33). 
When the clinical outcome was further analysed, it was noticed that P2RX7 
associated both with BD and MDD, whereas the SLC6A4 association signal came 
from MDD cases. The P2RX7 associated also with co morbid anxiety and 
alcoholism, psychotic features, and suicide attempts, with the most significant 
association signal gained with co morbid alcoholism. P2RX7 risk alleles also 
associated strongly with more time ill (p=0.0003 with rs2230912). This association 
was also evident when the differences in follow-up periods were taking to account 
and the age, gender, and the cohort was adjusted (OR=1.71 with 95% CI 1.30-2.26, 
p=0.0002). The effect of the genotypes on the clinical outcome is visualised in 
Figure 5.  
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Figure 5. The influence of P2RX7 genotypes on the clinical outcome relative to the 
time ill parameter. SD=Standard deviation.  
 
The most significant finding in this study was the plausible association of the P2RX7 
gene with mood disorder and the risk alleles effects on the clinical outcome, i.e. the 
risk alleles extend the time in illness within patients. There were two non-
synonymous variants that associated in a statistically robust manner and the 
association was evident in all three cohorts included in this study. Another 
associating variant was also allelic replication of previous studies, where the 
rs2230912 / Gln460Arg have associated with BD (Barden et al 2006), MDD (Lucae 
et al 2006), and anxiety (Erhardt et al 2007). The analyses made in large populations 
have been negative (Green et al 2009; Grigoroiu-Serbanescu et al 2009), but one 
reason for this discrepancy could be allelic heterogeneity, because there are many 
non-synonymous variants within this gene, both common and rare (Barden et al 
2006; Fuller et al 2009), thus there are many potential causative variants 
confounding the results in heterogeneous populations. The heterogeneity was also 
seen in this study, since two variants associated independently, i.e. the variants were 
not in high LD. This study also implies that this gene has a strong effect, particularly 
on more serious forms of mood disorders with comorbidities and longer time in 
illness. In addition, the familiality was an important factor in the association, since 
the association signal vanished when only the non-familial cases were included in 
Time in illness
 (%)
0
10
20
30
40
50
60
70
80
Homozygous
protective allele
Heterozygous Homozygous risk
allele
rs208294 rs2230912
SD = 32.0
SD = 34.6SD = 36.1
SD = 35.9
SD = 35.0SD = 35.8
 THL – 91/2012  66  Genetics Behind  
Mood Disorders 
the analyses. These factors could also explain why the studies in large populations 
have been negative (Green et al 2009; Grigoroiu-Serbanescu et al 2009), since the 
MDD cases in these large population studies have not been selected in any way, and 
in this study it seems that the association signal comes from a familial type of MDD 
and is most evident within cases that carry a serious form of the disease.  
The P2RX7 gene also associates with co morbidity disorders; most strongly with 
alcoholism. There is some previous evidence of shared genetic risk factors of 
alcohol dependence with MDD (Prescott et al 2000) and BD (Johnson et al 2009), 
and an unpublished finding of P2RX7 association with alcoholism in Finland 
(Mantere, submitted 2012).  
The exact role of the P2RX7 gene in the brain remains uncertain and it seems that it 
might have several distinct functions that can all mediate the effect of this gene on 
the susceptibility to mood disorders. These functions include its role in inflammation 
reactions, neurogenesis, neuroplasticity, and neurotransmitter (e.g. glutamate) 
release (Sperlagh et al 2006). Interestingly, the other associating variant 
(rs208294/His155Tyr) is a functional variant altering the function of the receptor: 
the associating Tyr allele increases the receptor activity after ATP activation 
(Cabrini et al 2005). The same Tyr allele has shown to predispose to higher 
vulnerability to chronic pain (Sorge et al 2012), thus strengthening further the 
connection of this variant and depression, since chronic pain is strongly linked to 
major depressive disorder (Ohayon and Schatzberg 2010). Consequently, the 
connection between P2RX7 and mood disorders seems to also be plausible 
biologically, but plenty of work is still required to explain the exact mechanism(s) 
behind this connection. 
This study strongly implies that P2RX7 gene is a very important factor in the 
aetiology of mood disorders, especially of MDD and its familial form. This gene 
seems to also be important clinically, since the risk alleles predispose to more severe 
disease form. 
5.1.3 Candidate genes of schizophrenia in bipolar disorder (III) 
There are some overlapping characteristics as well as common genetic susceptibility 
genes between BD and schizophrenia. Thus, some potential psychotic disorder 
candidate genes (DAOA, COMT, DTNBP1, NRG1 and AKT1)were surveyed here in 
the bipolar family sample, and their association with both bipolar spectrum disorder 
and psychotic symptoms were assessed. In addition, an assessment was made as to 
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whether these genes associated with potential endophenotypes of psychiatric 
disorders, i.e. with neuropsychological traits.  
No strong evidence of association between these candidate genes and disease status 
was shown here. The only nominally significant result from single SNP analyses in 
the whole study sample were gained with the functional variant of COMT rs4680 
and BD (P = 0.046). When only the familial cases were included in the analyses 
there was one additional variant in COMT (rs165599) showing nominal association 
with BD (P = 0.035) and two variants in DAOA (rs701567 and rs778326) showing 
nominal evidence of association with psychotic disorder (P = 0.031 and 0.018, 
respectively).  
Analyses against neuropsychological test variables revealed robust evidence of 
association of non-synonymous variant rs2391191/Arg30Lys of DAOA with 
visuospatial ability (P = 0.000005), visualized in Figure 6. The Lys allele, previously 
shown to be a risk variant for schizophrenia (Muller et al 2011), associated with 
better performance in this cognitive test. The same variant associated also with other 
traits assessing general intellectual functions as well as several traits assessing 
attention, memory, learning and, executive performance. COMT variant rs165599 
also showed evidence of association with several neuropsychological traits, most 
strongly with the same visuospatial ability as Arg30Lys of DAOA (P = 0.0007). 
There was no evidence of interaction of the effect of these two variants to the 
visuospatial ability, but an additive effect was seen. 
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Figure 6. Effect of the DAOA variant rs2391191/Arg30Lys genotype to the 
neuropsychiatric test results of Block design assessing visuospatial ability. SD = 
standard deviation. 
 
Although there was no strong evidence of association with the disease status, there 
was convincing evidence of association between the nonsynonymous variant of 
DAOA with general intellectual functioning, most robust with visuospatial ability. 
The DAOA gene is interesting, because it is a primate-specific gene encoding 
mitochondrial protein that promotes mitochondrial fragmentation and dendritic 
branching (Kvajo et al 2008) and it is also presumed to function in glutamate 
signalling (Chumakov et al 2002; Sacchi et al 2011). Mitochondrial dysfunction is 
hypothesized to be one of the factors affecting susceptibility to psychiatric disorders 
like BD, MDD, and schizophrenia (Fattal et al 2006; Rezin et al 2009).  
DAOA is one of the most robust schizophrenia candidate genes (Muller et al 2011) 
and its expression is elevated in the schizophrenic brain (Korostishevsky et al 2004). 
Recent rodent data has also demonstrated that mice expressing human specific 
DAOA gene have several behavioural changes that relate to many psychiatric 
disorders, like motor-coordination deficits, increased compulsive behaviours, and 
increased sensitivity to phencyclidine, an antagonist of glutamate (NMDA) receptors 
(Otte et al 2009). The schizophrenia risk allele of the associating variant, associated 
here with better performance, has been shown to associate with the reduced 
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thickness of the cortex of schizophrenic patients (Schultz et al 2011). These and our 
findings related to DAOA effects on intellectual functioning suggest an evolutionary 
perspective on psychiatric disorders, that act as a gate-away to more plastic brain 
structure enabling evolution of more complex brains, but at the same time 
predisposing to psychiatric deficiencies. 
This study further attests that the neuropsychiatric test results are useful 
endophenotypes for psychiatric disorders. Here, two highly potential psychotic 
disorder candidate genes, DAOA and COMT, associated strongly with block design 
assessing visuospatial reasoning within bipolar familial sample. This test defines one 
aspect of general intellectual functions. Visuospatial reasoning has been shown to be 
impaired in BD (Tiihonen et al 2005), as well as in healthy siblings of BD patients 
(Frantom et al 2008). The intelligence quotient has shown to be a high risk factor for 
schizophrenia and other psychotic disorders (David et al 1997). Thus according to 
these and our results, the endophenotypes could be partly common between BD, 
schizophrenia, and other psychotic disorders. There was no evidence here of 
interaction between DAOA and COMT that might lead to a cognitive phenotype, 
although there is a previous study showing interaction of these two genes affecting 
cognition (Nixon et al 2011).  
5.2 Replication of GWAS findings (IV, V) 
In studies IV and V, we wanted to survey if the new findings gained from the first 
three GWA studies (Baum et al 2008a; Sklar et al 2008; WTCCC 2007) show any 
evidence for association in the Finnish population either for BDI, mood disorder or 
their potential endophenotypes, that is, neurocognitive abilities or circadian 
phenotypes like circadian preference of daily activities and seasonal variation of 
mood and behaviour.  
A genotype was performed for the 76 associating variants from the first three GWA 
studies, as well as from meta-analysis (Baum et al 2008b). Altogether 13 variants 
showed evidence of association with BDI or mood disorder (P < 0.05) (Table 12). 
The associating variants spanned five distinct genomic areas or genes, including 
2p25.1 (nearest gene LPIN1), Sortilin-related VPS10 domain containing receptor 2 
(SORCS2), Deafness, autosomal recessive 31 (DFNB31), 18q12.3 (nearest gene 
Cadherin 7, type 2 (CDH7)), and SLC39A3. All the associations were modest, P-
values ranged from 0.044 to 0.001 (Table 12). Most of the variants that associated 
with the disease status, also associated with some of the potential endophenotypes, 
either with circadian phenotypes and/or neuropsychiatric traits. The most significant 
P-values were gained with DFNB31 and mood disorder (P=0.001) and seasonality of 
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sleep duration (P = 0.003); with SORCS2 and BDI (P = 0.004); and with CDH7 and 
visual attention (P = 0.006). In CDH7 gene, the risk allele of BDI associated with 
increased seasonal variations in social activity and mood (P = 0.017 and 0.028, 
respectively) and increased visual alertness reflected by improved performance in 
visual attention (P = 0.006). 
 
Table 12. The associations of GWA studies SNPs that replicated in Finnish bipolar 
family sample with P-value < 0.05. The quantitative trait associations with P-value 
lower than 0.001 are shown. 
     
BDI 
(N=214)  
MOOD 
(N=218)  Seasonality (N=127)   
Neuropsychological 
traits (N=159) 
Gene SNP P P 
Sleep 
length Weight Visual attention 
LPIN1 rs4027132  0.042  0.071  0.305 0.053   0.045 
SORCS2 rs4411993 0.006 0.014 0.207 0.438 0.741 
SORCS2 rs7683874 0.013 0.009 0.046 - 0.179 
SORCS2 rs10937823 0.004 0.005 0.046 - 0.168 
DFNB31 rs10982256 0.010 0.001 0.005 0.008 0.753 
CDH7 rs2850699 0.019 0.028 0.081 0.082 0.008 
CDH7 rs2850700 0.012 0.021 0.044 0.09 0.010 
CDH7 rs2850701 0.014 0.038 0.043 0.065 0.006 
CDH7 rs2658046 0.021 0.078 0.091 0.096 0.009 
CDH7 rs976882 0.025 0.039 0.1 0.098 0.006 
CDH7 rs12970791 0.044 0.097 0.128 0.162 0.016 
CDH7 rs1444067 0.018 0.023 0.073 0.067 0.006 
SLC39A3 rs4806874  0.034  0.259  0.583 0.482   0.620 
 
DFNB31 gene, that associated most strongly with broad mood disorder status is a 
gene that causes sensorineural hearing loss when mutated (Mustapha et al 2002). 
The gene product called whirlin is shown to be important in the elongation of 
stereocilia of sensory hair cells (Mburu et al 2003). Besides being expressed in the 
inner ear, it is also expressed in the developing brain and in the retina (van Wijk et al 
2006). In addition, being a causal variant in nonsyndromic hearing loss, it is also 
responsible for Usher syndrome type II (Ebermann et al 2007) that is characterized 
by congenital hearing loss and onset of retinitis pigmentosa and thus loss of vision 
during or after puberty (Smith et al 1994). Thus, it is interesting that the gene 
associated also with seasonality (e.g. seasonal changes in sleep duration; P = 0.005), 
a phenotype that requires visual information.  
SORCS2 gene is highly expressed both in the developing and the mature central 
nervous system in mice, localised to the dopaminergic nuclei among other places 
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(Rezgaoui et al 2001). The gene belongs to the Vps10p-D family of proteins that are 
important in the development of neuronal structures and thus take part in the 
plasticity of the brain and it is also hypothesized to function as an endocytic receptor 
and thus as a sorter of neurotransmitter and growth factor receptors (Hermey et al 
2004). These functions and recent association findings make it interesting as a 
susceptibility gene for BD.   
CDH7 belongs to the cadherin superfamily, which are transmembrane glycoproteins 
that regulate, among other things, brain development in several ways, including cell 
sorting, migration, and axon outgrowth (Luo et al 2004). It was discovered in 2000 
and shown to be expressed in testis, prostate, and brain, also during development 
(Kools et al 2000). Chicken and rat homologues of this gene and its expression are 
widely studied, and it has shown to be expressed in neurons in the visual pathway 
and retina in chicken (Wohrn et al 1998), and in the developing eye and in the retina 
in mice (Faulkner-Jones et al 1999). The variants associating here are located in the 
genomic area 250 kb upstream of the CDH7 gene. The variants associate with the 
diagnosis of BDI and with circadian clockwork, seasonal variations, visual attention, 
and visual working memory. All the endophenotypes that indicate association are 
processes that are related to neurons using visual information; in circadian and 
seasonal phenotypes providing information about light-dark transitions, and in 
WMS-R tests, the ability to manage and remember visual information. This is a 
second replicated gene of GWA studies that is related to vision and that associates in 
Finnish sample with mood disorders, thus it implies that the etiology of these 
disorders could be partly reflected by the ability to adapt to the light-dark transition 
in northern latitudes. 
The strength of GWA data is that they provide new potential susceptibility genes 
that have not been found in previous linkage and candidate gene studies that are 
based on researchers own reasoning about genes’ likelihood to function behind 
psychiatric phenotype. When doing GWA studies you need not have any advance 
hypothesis about the genes’ function, instead you can find new surprising genes 
which were not known beforehand to have important function in brain. A wide 
variety of human genes are expressed in brain tissue as shown in microarray studies 
(Ramskold et al 2009; Velculescu et al 1999), although the regulation of expression 
has shown to be complex (Ramskold et al 2009). So, the GWA studies guide the 
way of basic brain function studies and this way might lead to new insight that may 
eventually also guide drug development.  
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6 CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
Despite the shift of genetic research to the era of large scale GWA studies and 
availability of the whole human genome sequence, the genetic background of MDD 
and BD remains largely unknown. Thus, hypothesis-based studies are still valid, in 
particular when performed in homogenous populations with detailed phenotypic 
information available for further dissection of the heterogeneous and complex 
phenotypes to those with genetically simpler architecture. This study implies that 
some of the classical candidate genes of mood disorders, including variants from 
BDNF, P2RX7, and SLC6A4 have an effect on the disease susceptibility in Finland 
(Study I and II), and that some psychotic related candidate genes (DAOA and 
COMT) have an effect on general intellectual functions that are potential 
endophenotypes of psychiatric disorders (Study III). It also showed that some of the 
new GWA study findings for BD associate with BD also in the Finnish population 
(Study IV and V).  
All results that were gained in this thesis were conducted with relatively small 
samples and thus they should be replicated in bigger samples to ensure that these 
genes have a role behind mood disorders in Finland. Furthermore, most of the P-
values achieved were only nominal when taking into account the number of tests 
done. We also cannot rule out the role of the genes having negative association 
results in Finnish mood disorder, since the SNP coverage in large genes such as 
NTRK2 were too sparse. In addition, the finding that DAOA associates with 
neurocognitive function should be replicated in a population based sample to 
establish if there is association in a normal population, or is the association related to 
the disease phenotype.   
This study implies that at least some of the genetic background of MDD and BD 
might be shared, as the P2RX7 association was evident in both MDD and BD (Study 
I and II). Hence, although recurrent MDD and BD are clinically defined as separate 
illnesses, at least part of their underlying genetic and biological factors are shared as 
has been also shown in studies on twins and high risk families. This also fits well 
with the clinical observations on their similar co-morbidity disorders, such as 
alcoholism, and the shared fluctuation of mood, which is one marker of familial type 
MDD (Kendler et al 2007; Levinson et al 2003).  
This study also showed that familial background of cases has an effect on the 
findings of the genetic studies. This is plausible since it is likely that the familial 
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subtype of MDD is more homogenous than sporadic cases of MDD. Consequently, 
the lack of success of the large GWA studies on MDD might result from selection of 
cases without taking into account their familial background. Accordingly, in our 
mood disorder cohort study (II), the association signal of P2RX7 vanished 
completely when analyses were performed using cases with no familial loading.  
The importance of selection of cases was seen also in linkage studies of MDD in a 
Utah pedigree sample (Abkevich et al 2003; Camp et al 2005), where findings from 
linkage studies in cases with both r-MDD and single episode MDD, as well as BD 
cases (Abkevich et al 2003), were completely different from those in cases with 
early onset r-MDD as well as anxiety disorder cases (Camp et al 2005).  
According to the latest GWA studies, it seems that the CDCV theory (common 
diseases explained by common variants) does not fit to psychiatric disorders as well 
as originally anticipated, and the issue of “missing heritability” has been a question 
of interest in the latest reviews (Gershon et al 2011). There are many possible 
explanations for this discrepancy. One is that rare variants play a more important 
role in the aetiology of mood disorders than previously thought and these variants 
might be distinct in different populations and families. That might also explain the 
huge variety and expansion of linkage peaks throughout the genome in the 
traditional linkage studies. Another possibility is that the heterogeneity of the 
genetic component contributes to the aetiology of mood disorders, even within one 
predisposing gene, which seemed to be the case also for P2RX7 (Study II). While all 
of these can be true, the most plausible explanation is that the phenotypes of MDD 
and BD are too broad, which leads to the confounding results seen in genetic studies, 
since the different aspects of broad mood disorder phenotypes are affected by 
distinct genetic susceptibility genes. Thus, analysis of huge sets of samples with 
thousands of genotyped individuals in future GWA studies might not necessarily 
lead to the discovery of the missing heritability, but instead to discovery of new low 
risk alleles. They will definitely reveal important etiological factors for the disease 
and might help to develop new, more efficient drugs, but they will not tell the whole 
story of genetics behind mood disorders.  
The use of endophenotypes and information on co-morbidity seem to be highly 
effective in genetic studies of mood disorders. Co-morbid conditions homogenise 
the case population, and thus enables the search for susceptibility variants also in 
smaller study samples. GWA data have shown that in order to find genome-wide 
significant associations for BD (and MDD) thousands of cases are needed in the 
study population (Chen et al 2011; Sklar et al 2011), but if additional information on 
the selection of case sample, such as co-morbidity (Kerner et al 2011) or 
temperament (Greenwood et al 2012) are used, genome-wide significant results 
might also be obtained with smaller sample sizes (Greenwood et al 2012; Kerner et 
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al 2011). Thus the complications of heterogeneous phenotype could be overcome by 
thorough phenotyping of the individuals. 
A considerably interesting finding of this study was the evidence that the risk alleles 
of psychiatric disorders seems to improve the performance in neuropsychiatric tests, 
such as in tests assessing general intellectual functions and visual attention and 
memory. This was seen with BDNF, DAOA, and CDH7 genes (Studies I, III, and V). 
It implies that the reasons why psychiatric disorders persist in human populations 
are partly due to the benefits that the risk alleles give to the carriers by enhancing 
their cognitive abilities. Thus, it seems that the same neurobiological alterations (e.g. 
enhanced neuronal plasticity) that improve the risk allele carriers’ cognitive 
functions, predispose the more vulnerable individuals for psychiatric disorders. 
This study further confirms the fact that the genetic background of mood disorder is 
highly polygenic. Even in the quite homogenous Finnish population, the allelic 
heterogeneity was evident, for example in P2RX7 association results. This study also 
illustrates that it is beneficial to use homogenous populations, like the Finnish 
population, in genetic studies, because it enables the realization of statistical 
significant P-values with smaller sample size. The downside is that at the same time 
you could only find certain genetic susceptibility genes that are enriched in that 
specific population.  
One future approach that could lead to the discovery of the hidden causative variants 
of mood disorder is genome-wide sequencing. This laborious approach is now 
available and will eventually reveal all the genetic variance between humans, 
including rare SNPs and CNVs. These future studies might reveal new predisposing 
variants, also for mood disorders. 
The functions of the genes that showed association in this study are still poorly 
understood. Thus, it would be highly interesting to study the functions of DAOA, 
P2RX7, and CDH7 in brain in more detail. In addition, the effects of associated 
functional variants of DAOA and P2RX7 would be interesting to survey in cell and 
animal models to eventually discover how their effects are passed to mood and 
cognitive functions. Overall, functional studies are crucial in the future, since the 
new mapping methods will reveal new susceptibility genes whose function in brain 
will be unknown. Collectively, before any new drug development based on these 
findings can be made, the exact role of these new candidates in the brain needs to be 
revealed.  
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